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Abstract 
Germline BRCA mutations underlay a significant risk for breast and ovarian cancer 
that increases in age. BRCA mutations are usually associated with the most aggressive 
subtypes of these cancers such as triple negative breast cancer and high-grade serous 
ovarian cancer. Conventional chemotherapeutic or hormonal therapies do not address the 
molecular deficiencies responsible for their resistance and there is a high rate of 
recurrence. Targeted therapy that can address the unique molecular features in these 
subtypes of cancer is the only way to cure the disease or, at the very least, improve 
patients’ quality of life.   
Homologous recombination repair is an accurate repair pathway that utilizes a copy 
of a homologous sequence to relay information to the break site. Cancer cells copy their 
DNA extensively meeting the principle demand for this high-fidelity repair pathway. 
Homologous recombination repair is utilized by cancer cells to cope with the most 
challenging forms of DNA damage such as DNA double strand breaks, stalled replication 
forks, adducts, and interstrand crosslinks. Among the key proteins in homologous 
recombination repair, RAD52 activity promotes cancer cells’ tolerance and survival. 
Therefore, there is a therapeutic opportunity in inhibiting RAD52 activity to push DNA 
damage levels in homologous recombination repair-deficient tumors beyond the limits of 
viability.  
One of the early events in this repair is resection of the broken strand and generation 
of single strand DNA. Replication protein A cover and protect those strands and interact 
with key DNA repair proteins. RAD52 activity in DNA repair is dependent on its 
 
 
interaction with replication protein A. The hypothesis of this thesis is that it is possible to 
inhibit RAD52 activity by inhibiting its interaction with RPA and this inhibition will 
have therapeutic benefits for cancer patients. We explored the binding activity and 
affinity of the RAD52 interaction with RPA. Kinetic, and thermodynamic parameters 
dictating this protein:protein interaction  were measured. The characterization of 
RAD52:RPA interaction data guided remapping of the RPA interaction domains on 
RAD52. To target RAD52 activity by inhibiting its interaction with RPA, we designed an 
in vitro fluorescent-based protein-protein interaction assay. This assay was further 
optimized for high throughput settings with a robust signal, minimal steps, statistical 
accuracy, and low cost. We screened over 100,000 compounds to look for small molecule 
inhibitors. Eleven hits were found and five were selected for their high EC50 values. 
Three of the five hits are FDA approved drugs and were selected for cytotoxicity tests in 
BRCA-deficient cell lines.   
The outcome of our characterization for these three candidate small molecule 
inhibitors may shed light on the variation of their efficacy and sensitivity among breast or 
ovarian cancer patients with BRCA-defective pathway versus those with none. 
Additionally, we present fluorescent-based protein-protein interaction assay as an 
affordable method to detect many protein:protein interactions in low-scale or high 
throughput settings applicable to finding small molecule inhibitors or aptamer modulators 
for protein:protein interactions. 
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Chapter 1 
1.1. Introduction 
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1.1.1. Normal cell division and DNA damage repair machinery. Regulation of cell 
division is essential for tissue homeostasis. This regulation involves utilization of 
molecular signals and critical decision-making regulated at discrete stages of a cell’s 
lifecycle [1]. A major driver of this decision-making process is DNA damage due to 
metabolic or environmental insults. Cells response in the face of these challenges 
involves initiating DNA repair processes while activating cell cycle checkpoints to allow 
the time needed for repair. Ataxia telangiectasia mutated (ATM), AT and Rad3-related 
(ATR), and DNA-dependent protein kinase, for example, are kinases that regulate the 
DNA damage response by establishing phosphorylation cascades in cell cycle checkpoint 
kinases and support the initiation progression of the appropriate repair mechanisms [2-4]. 
Cells resort to apoptosis when the damage is beyond their repair capacity [5]. DNA repair 
pathways have a common capacity of repairing DNA lesions but vary in their efficiency 
as a function of the site, nature of the lesion, cell’s genotype, stage in the cell cycle, and 
the risk of mutagenesis in the process. Figure 1.1 summarizes the different DNA lesions 
and corresponding specialized repair pathways [6]. 
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Figure 1.1 Types of DNA damages and repair mechanism. DNA is damaged in various ways 
during normal metabolism or by exogenous factors. The top panel of boxes show the types of DNA 
damage and arrows point down to specialized repair systems. DSBs are repaired through NHEJ or 
HR. The beneficial outcome of different repair pathways is measured by promoting cell survival and 
variation in that is indicated by the number of upward arrows. Accurate repair pathways such as HR 
are least mutagenic and that is indicated by an upward arrow. Less accurate repairs are mutagenic and 
indicated by a downward arrow. BER is involved with small DNA adducts. Transcription-coupled 
repair (TCR) deals with lesions that block elongating RNA polymerase. Transcription-coupled 
nucleotide-excision repair (TC-NER) repairs transcription-blocking bulky adducts.  The path of DNA 
polymerases can be stalled due to encountered adducts or cross-links. Such damage can be repaired, 
bypassed (template switching or translational synthesis). Figure is adapted from Jan Hoeijmakers, 
2009: The New England Journal of Medicine. 
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The level of challenge for the cell to repair DNA damage varies. For example, DNA 
single strand breaks are frequent but relatively undemanding. These breaks are ligated 
either directly within the phosphodiester backbone or after removal of abnormal 
structures with as the intact strand holding the ends together [7]. Single strand breaks are 
inevitable intermediates in base excision repair BER, nucleotide excision repair NER, 
and mismatch repair MMR are among the main DNA repair pathways. 
The most taxing form of DNA damage in a cell is the DNA DSB [6]. DSBs are an 
unavoidable consequence for a number of physiological processes such as the process of 
relaxing DNA supercoils, or during normal cell death by apoptosis [8]. Generally, the 
availability of a template on a sister chromatid makes it possible to search for 
homologous or near-homologous sequence to copy information accurately in HRR 
pathway. This is possible when damage occurs during the S or G2 phase of the cell cycle, 
otherwise nonhomologous end joining (NHEJ) is an error-prone alternative repair choice 
for non-proliferative cells in G0 and G1 [9, 10]. NHEJ simply involves alignment and 
ligation of broken strands. Lahav’s and coworkers avoided the approach of fixing cells 
after damage to measure the type of repair activity in relation to cell cycle phase. Instead, 
they employed long-term, time-lapse microscopy and fluorescent reporters to obtain 
quantitative data that suggested a direct link between HRR and increased active 
replication events (Figure 1.2) [11]. Therefore, they argued that it is not the availability of 
replicated DNA that dictates the transition to HRR, but rather the extent of active 
replication. Single strand annealing (SSA) is another repair process for DSBs occurring at 
site of already existing homology, in particular repetitive DNA sequences [12]. 
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Figure 1.2 Repair choice by HRR or NHEJ and cell cycle. 53BP1 is a DNA damage 
response protein which forms subnuclear compartments called foci that provide experimental 
assessment of DSBs in cells. RAD52 is a protein that forms foci at DSB sites that are 
committed to HRR. (A) Heat map showing the proportion of DSBs repaired by HR (RAD52-
mCherry foci) post damage (53BP1-YFP foci) shown as a function of the time (hours) from 
the induction of DSBs and cell-cycle progression (gray bar on the left). Higher proportion of 
HRR activity is observed (red color) with longer extent in replication phases of cell cycle.  
(B) The proportion of DSBs repaired by HRR in individual cells post damage is plotted 
against their cell-cycle progression at the time of damage indicated by the reference bar on 
top. The three lines shown are the median (black line), 25th, and 75th percentile (dashed blue 
lines above and below the black line). 
(C) Relative accumulation of RAD52 foci in individual cells after damage is plotted against 
cell-cycle progression. The three lines shown are the median (black line), 25th, and 
75th percentile (dashed blue lines above and below the black line).  
(G) A model summarizing collective data from time-lapse microscopy and fluorescent 
reporters and represents the transition between NHEJ and HR with cell-cycle progression. In 
G1, DSBs are exclusively repaired by NHEJ. HRR activity gradually increase as cells 
progress into early S phase and a peak is reached by mid S phase. HRR then decreases 
gradually as cells progress toward late S and G2. Cells in late G2 repair their DSBs almost 
entirely by NHEJ.  
Figure is adapted and modified from Karanam et al., 2012: Molecular Cell. 
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1.1.2. The tolerance for DNA damage by cancer cells. Cancer cells usually exhibit an 
abnormal extent of active replication with a large capacity to divide and replicate their 
DNA [13]. Accompanying these events is a heavy load of genotoxic stress that when 
combined with cytotoxic treatments, results in an intensified amount of DNA damage 
mostly in the form of DSBs. Stalled replication forks, interstrand crosslinks, and adducts 
are prevalent in the stressful tumor environment and tend to induce more DSBs. At this 
level, normal cells would have exhausted their repair capacity mechanisms and resorted 
to cell death to prevent the propagation of damage and preserve genomic stability. Cancer 
cells on the other hand are not only able to survive, but also are propelled into further 
expansion. Resistance to cell death becomes a hallmark for them and they acquire the 
ability to maintain the status quo by tolerance for genomic instability [14].  
1.1.3. The rise of malignancies and the vision for targeted therapy. The vitality of a 
tissue is judged by the ability of its cells to divide with orchestrated control throughout its 
life cycle. Cells differentiate into their fateful identity through a tightly regulated process. 
This is no surprise, given that a vast portion of our genome encodes regulatory elements 
and a much smaller part encodes functional proteins. Although this may seem to be a 
rigid process, we now know that a degree of plasticity is offered by our chromatin 
structure and associated transcriptional regulators. For example, studies have shown that 
in the face of some challenges, the responsibility of DNA replication can be handed over 
to other classes of DNA polymerases with more malleable base-pairing capacity [15]. 
This plasticity allows for an appropriate and adaptive response to environmental or 
metabolic stimuli. Flavahan and colleagues postulated that when a cell is faced with a 
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challenge, this plasticity allows it to assume alternative functional and regulatory 
pathways [14]. For example, cells can shift DNA damage response or repair to alternative 
mechanisms or pathways [16]. While these alternative pathways may contribute to a 
cell’s fitness in the face of potentially pro-oncogenic stimuli, some can drive the cell into 
malignancy. This unfortunate consequence itself gives cancer cells distinctive molecular 
features when compared to normal ones, a concept of great importance to researchers 
interested in shifting cancer therapeutics to specific and targeted approaches.  
Current promising therapies involve targeting pathways that are vital to cancer cells’ 
survival, proliferation, and the maintenance of their tumor microenvironment [17]. 
Components of the DNA damage response are at the center of these processes and are, 
not surprisingly, among the most frequently mutated in cancer [18]. Evidence includes 
the acceleration of hepatocarcinogenesis by constitutive upregulation of different DNA 
repair pathways [19], the upregulation of the HRR component RAD51 [20-22], or the 
downregulation of tumor suppressors BRCA1/2 [23] in driving breast and ovarian 
cancers.  
1.1.4. Homologous recombination repair machinery. HRR is initiated by a resection 
process at the DSB site in a 5′-3′ direction by the Mre11-RAD50-NBS1 (MRN) complex 
producing exposed ssDNA on opposite ends of the break site (Figure 1.3, step 1, 2, and 3) 
[24]. This outcome is immediately addressed by replication protein A (RPA) binding 
ssDNA at the break site. Aside from physical shielding and protection, RPA contributes 
to an accurate repair choice by preventing insufficient homologies to lead the repair 
process or haphazard end joining [25]. In addition, RPA prevents the formation of DNA 
secondary structures during replication and repair, thereby contributing to the 
10 
 
maintenance of genomic stability [26, 27]. This role for RPA continues until RAD51 
takes over the repair process by forming presynaptic filaments to catalyze homologous 
strand invasion and annealing [28]. An active ongoing HRR is usually experimentally 
observed in the form of discrete subnuclear structures called RAD51 foci [29]. The 
replacement of RPA with RAD51 requires a mediator protein.
11 
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Figure 1.3 HRR and BRCAness. A schematic representation of the repair steps of 
DSBs by HR. Tumor suppressor proteins involved in the process are shown in bold. 
BRCA1 is an example of those proteins and is essential for the early step in repair where 
MRE11A-NBS1–RAD50 (MRN) complex detects and bind broken strands. This 
complex, along with recruited ATM, leads the resection process and generation of 
ssDNA on either side of the break. The next tumor suppressor proteins in the process is 
BRCA2, which localizes RAD51 to the exposed ssDNA regions to perform homology 
search. PALB2 is an additional tumor suppressor that is crucial for the localization of 
BRCA2. Next, nucleoprotein filament formed by RAD52 recombinase invade an intact 
DNA double helix containing a homologous, sequence (indicated in red). This sequence 
is used by DNA polymerases as a template to synthesize new DNA that repair the break. 
Finally, resulting cross-over structures are resolved by DNA ligases and endonucleases. 
Blue branching boxes on the right represent the vulnerabilities of cells with defected 
HRR and ways to exploit that vulnerabilities in targeted therapy. For example, 
pharmacological inhibition of PARP leads to accumulation of DSBs that cannot be 
efficiently repair by HR when BRCA1, PALB2, or BRCA2 are mutated. Also, loss of 
HRR probably cause shunting of DSBs repair to alternative mutagenic DNA repair 
pathways such as NHEJ resulting in gross chromosomal instability and cell death. Figure 
is adapted from Lord and Ashworth, 2016: Nature Reviews Cancer. 
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1.1.5. The status of BRCA1/2 in RAD51-mediated HRR. BRCA1 and BRCA2 play a 
crucial role in both detection and repair of DSBs. BRCA2 joins BRCA1 in a complex that 
co-localizes with RAD51 and activates DSB repair [30, 31]. BRCA1 is implicated in 
regulating the activities of the DNA repair by HRR such as the formation and function of 
the MRN complex (Figure 1.3, step 3) [32-34]. 
While BRCA1 function in HRR is focused on recruitment, activation, and assembly 
of repair components, BRCA2 plays a more direct role. For RAD51 subunits to load and 
nucleate a protein filament on the ssDNA strands, RPA must be displaced. In eukaryotes, 
the BRCA2 proteins are the main mediators of this process [35]. Heyer and colleagues 
have shown that BRCA2 plays an integral role in HRR not only as a mediator, but as a 
driver of the process as it stimulates RAD51 binding to ssDNA [36].  In fact, direct 
interaction and regulation of RAD51 repair activities defines the role of BRCA2 in 
HRR(Figure 1.3, step 4) [37].  
1.1.6. The significance of ‘BRCAness’ in cancer. Germline mutations in the tumor 
suppressor BRCA1, BRCA2, or PALP2 are associated with the majority of hereditary 
breast and ovarian cancers [38, 39] and contribute, less frequently, to the risk for prostate, 
pancreas, fallopian tube, bile duct, stomach, and male breast cancer [40-43]. Moreover, 
BRCA1 was identified as FANCS while BRCA2 as FANCD comprising the Fanconi 
anemia-BRCA pathway. Mutations are also associated with predisposition to acute 
myelogenous leukemia and epithelial cancers [44-46]. In a broad sense, BRCAness is 
defined as defect in DSBs repair by HR. Figure 1.3 depicts DSBs repair by HR and the 
significance BRCA1, BRCA2, and PALP2 in the process [34]. Tumors with BRCAness 
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share molecular features across their different subtypes [47]. Hallmarks of BRCAness’ 
include basal-like phenotype, ER-negativity, EGFR expression, sensitivity to DNA-
crosslinking agents, and loss of RAD51 foci formation [48]. BRCAness predisposes 
women to the most aggressive subtypes such as triple-negative breast cancer (TNBC) 
[49]. The majority of high-grade serous carcinoma (HGSC), which account for over half 
of all ovarian epithelial tumors with the lowest survival rate, demonstrate BRCAness 
[50]. TNBC and HGSC remain challenging in the face of available conventional hormone 
or cytotoxic chemical therapies due to lack of hormone receptors, poor prognosis, and 
high rate of recurrence [51, 52]. Due to the significance of the BRCAs in DSB repair, 
exploiting their malfunctions can offer selective killing of cancer cells.  
1.1.7. The status of RAD52 in RAD51-mediated homologous recombination repair. 
Knowing the indispensable role of Rad52 and its epistasis group of genes in HRR in 
Saccharomyces cerevisiae, West and colleagues were motivated to investigate its status 
in human HRR. Accordingly, they developed an in vitro system using purified human 
RPA, RAD51, and RAD52 proteins to reconstitute the HRR processing of DSBs. In 
addition to their detailed finding of the overall repair process, RAD52 was found to 
function in stimulating RAD51 interaction with ssDNA [53]. However, the significance 
of RAD52 remained perplexing as two in vivo model studies at that time showed the 
unhampered ability of mammalian cells to mount an HRR response in the absence of a 
functional RAD52. The first of these studies measured the number of RAD51 foci after 
gamma-irradiation of normal verses. RAD52-/- in the DT40 chicken B cell lines [54]. No 
difference was found in the formation or cycling of RAD51 foci indicating an unhindered 
HRR process. Another independent study found that RAD52 knock-out mice were 
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aphenotypic and relatively similar in their ability to mount HRR compared to mice with 
wild-type RAD52 [55]. Interest in RAD52 function in DSB repair eventually sparked 
with the series of siRNA targeting studies by Simon Powell and collaborators that 
demonstrated dependence of cells deficient in BRCA2 function on RAD52 to carry 
RAD51-mediated HRR of DSBs [56]. RAD52 indeed is capable of taking over this 
BRCA2 function in HRR given its reported direct interaction with RAD51 [57]. In fact, a 
synthetic lethal relationship was concluded to exist between RAD52 and BRCA2 as well 
as BRCA1 and PALB2 as explained in the next section [58]. 
1.1.8. BRCA proteins & RAD52: Synthetic lethality relationship. In the face of 
mounting DNA damage challenges cancer cells become “addicted” to DNA repair 
pathways. These alternative pathways are usually not the same ones that led to their 
malignant phenotype. Having lost the function of their main DNA repair pathway(s) by 
oncogenic alterations, selective cell death can be achieved by toxic accumulation of DNA 
damage when the alternate pathway(s) is targeted by an inhibiting or a modulating agent. 
Cancer cells deficient in BRCA1/2 function show reliance on RAD52 to mediate 
RAD51-facilitated HRR and SSA of DSBs [59-61]. These findings motivated a number 
of studies aimed at targeted cancer therapy exploiting the synthetic relationship between 
the BRCAs and RAD52. Indeed Cramer-Morales and colleagues demonstrated potential 
targeted therapeutic effects in leukemia cells harboring impaired BRCA1 function by 
targeting RAD52 activity [60]. A number of similar efforts followed to find ways to 
inhibit RAD52 to induce selective cell death in BRCA-deficient tumors and recently 
reviewed by Spies et al.[62-65]. 
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1.1.9. RAD52 and tumorigenesis, beyond filling-in for BRCA2. Targeted therapy 
efforts rely on identifying specific molecular factors that enable tumor cell survival and 
growth. Recent expanded understanding of RAD52 activity suggests that it can assume 
“emergency” roles and is specifically recruited to DNA replication stress sites [66]. 
Therefore, RAD52 appears to promote tumorigenesis extending beyond the narrow scope 
of providing a backup pathway in BRCA-deficient cells. For example, RAD52 
upregulation was reported in liver cancer [19] and RAD52 is required for the recovery of 
a collapsed replication fork [67, 68]. RAD52 is also the main player in SSA, a repair 
process that was reported to increase in some cancers [69].  Moreover, some cancer-
associated genes are reported to be enriched for repetitive sequences suggesting 
potentially increased SSA activity [70]. SSA repair activity of DSBs was also observed to 
increase in response to general decrease in RAD51-mediated HRR [71]. 
Recently a new inverse strand exchange activity for RAD52 was identified to drive 
RNA-templated DSBs repair [72].  It is no surprise, therefore, that targeting RAD52 
activity was not only selectively lethal to BRCA-deficient cell [56], but also suppressed 
cancer stem and progenitor cell expansion [60], and even augmented the activity of the 
tumor immune response [73]. 
1.1.10. Approach to target RAD52 repair activity. RAD52 function has been 
correlated with several stress-induced responses that foster survival during uncontrolled 
cell growth. Targeting RAD52 is detrimental to BRCA-deficient tumors and may very 
well deprive other types of tumor microenvironments of an essential survival and 
maintenance factor. Different SMIs and aptamers have been identified and developed 
however, the common goals have been targeting RAD52 interaction with substrate DNA 
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and RAD52 annealing activity. Among the early approaches was the targeting of a 
residue on the RAD52-DNA binding domain (F79) by an aptamer to achieve synthetic 
lethality in chronic myelogenous leukemia cells deficient in BRCA1 activity [60]. More 
work followed to find a SMI to disrupt the ring structure of RAD52 and prevent the 
formation of the presumed ssDNA-binding grooves [74], RAD52 SSA repair activity of 
DNA [63], and inhibition of RAD52-ssDNA inhibitors [62, 64]. The outcomes of these 
studies are promising and motivating, however, our expertise in DNA repair proteins 
suggests for a different approach.  
Aside from the innate ssDNA annealing capability demonstrated in vitro by 
Sugiyama and colleagues [75], all RAD52 repair activities described earlier require 
interaction with RPA. Given its abundance [76] and high intrinsic affinity for ssDNA 
[77], any single stranded region formed is immediately bound by RPA. This strong hold 
of DNA enables RPA to coordinate repair components arriving at the break site. Indeed, 
RAD52 function in HRR seems to be dictated by RPA. Early studies demonstrated that a 
mutated RPA-binding domain on Rad52 impairs its recruitment to the damage site [78]. 
We have shown that in the absence of RPA, RAD52 exists in rings and aggregates of 
rings and that monomeric RAD52 purifies in a stable complex with RPA-ssDNA. RPA 
was capable of promoting the breaking of the RAD52ring structure supporting RPA role 
in RAD52 activity [79]. In the recently described role for RAD52 in RNA-templated 
DNA DSB repair, the addition of RPA noticeably stimulated the repair activity [72]. 
Inhibiting RAD52’s interaction with RPA is probably detrimental to all its functions in 
repair. The feasibility of this approach, however, has been met with reluctance as it 
involves targeting of a PPI with small molecule inhibitors. Among candidate cancer 
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targets, PPIs were historically discounted due their large and discontinuous epitopes. 
However, protein mutations are among the drivers for tumorigenesis as well as the 
development of resistance [80]. Remarkable strides were achieved recently in 
pharmaceutical targeting PPI of the Bcl-family of proteins to impede cancer cell survival 
[81]. These recent advances have improved the outlook on targeting PPIs for the 
development of new therapies. 
The hypothesis of this thesis is that RAD52 can be as a targeted through its 
interaction with RPA. This PPI constitutes a repair pathway to mediate RAD51 activity in 
HR offering a backup survival path in BRCA-deficient tumors. The therapeutic value of 
targeting RAD52 activity can apply to several types of tumors. We investigated both 
kinetic and thermodynamic parameters of the RAD52:RPA complex deciphering 
important domains of interactions. Our work here acknowledges that there are still many 
potential targets to explore for targeted therapeutics which raises the need for a reliable 
high throughput experimental technique to search for compounds capable of modulating 
the function of a target. To address this need and contribute to the efforts, we developed a 
PPI assay and utilized it to confirm interacting domains. The assay was optimized for use 
in high throughput settings and used to screen over 100,000 small molecules looking for 
inhibitors. Finally, we detail our cell-free and cell-based methods characterizing 
candidate SMIs to determine their therapeutic value. Characterization results of some hits 
show reduced survival of cancer cells when RAD52 interaction with RPA is inhibited and 
thus validate the hypothesis. 
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Chapter 2 
A simple fluorescent assay for the discovery of 
protein-protein interaction inhibitors 
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2.1. Abstract   
Due to the therapeutic potential of targeting PPIs there is a need for easily executed 
assays to perform HTS of inhibitors. We have developed and optimized an innovative and 
robust fluorescence-based assay for detecting PPI inhibitors, called FluorIA (Fluorescence-
based protein-protein Interaction Assay). We use targeting the PPI of RAD52 with RPA as 
an example and describe the FluorIA protocol design and optimization for future HTS of 
large chemical libraries. Here EGFP-tagged RAD52 detects the PPI using RPA coated, 
black microtiter plates and loss in fluorescence intensity identifies SMIs that displace the 
EGFP-tagged RAD52. The FluorIA design and protocol can be adapted and applied to 
detect PPIs for other protein systems. This should push forward efforts to develop targeted 
therapeutics against protein complexes in pathological processes.   
2.2. Introduction 
High throughput screening (HTS) has evolved into a specialized key drug discovery 
tool [82, 83]. With this advancement, the ambitions of scientific research shifted from the 
delivery of indiscriminate agents to drugs with more selectivity for the target. Current 
targets in cancer, for example, include abnormally expressed proteins, tumor 
microenvironment components, and alternative survival pathways adapted by tumor cells 
[17]. In each of these categories of therapeutic approaches, targeting pathologic PPIs are 
as promising as targeting mutated genes. PPIs orchestrate the signaling of normal cellular 
proliferation, the very trait that defines malignancies when deregulated. To sustain chronic 
proliferation, cancer cells acquire alternative signaling pathways defined by unique and 
specific PPIs [13]. 
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Modulation of PPI with small molecules was, justifiably, described as “undruggable” 
or the “high-hanging fruit” [84]. Over the past two decades, however, interest in targeting 
PPIs increased with advanced knowledge of proteomics. Large PPI interfaces, for example, 
once regarded as a major challenge to target with small drug-like molecules are now 
desirable to bolster selectivity [85, 86]. Also, the community no longer thinks SMIs must 
mimic the interacting partner of the targeted protein and this realization led to a more 
comprehensive screening of available libraries [87-89]. Mutational studies demonstrated 
that only some residues in the PPI, or “hot spots”, contribute the majority of binding energy 
for the SMIs to bind and block the targeted protein partner from binding[85, 90]. With this 
finding, the quest for targeting PPIs with SMIs became plausible and the development of 
robust and cost-effective assays for HTS of SMI libraries for PPIs are in demand. 
Successful HTS screens that target PPIs include nuclear magnetic resonance [91], 
differential scanning fluorimetry[92], Fluorescence polarization/anisotropy[93], virtual 
screening with docking[94] and cell-free, enzyme-linked immunosorbent assay (ELISA) 
[95, 96].  
Here, we describe our design and optimization of a fluorescent-based protein-protein 
interaction assay (FluorIA) applicable for HTS. As an example, we applied our assay to 
target the PPI of two important DNA repair proteins: RAD52 and replication protein A 
(RPA). RAD52 is a multi-domain protein that mediates homologous recombination repair 
of DNA double-strand breaks, a role mainly played by BRCA2 in mammalian cells [36, 
97-99]. Tumor cells that have lost BRCA2 function rely on RAD52 to survive the breaks 
encountered from replication stress or cytotoxic treatments [61, 100, 101] and this presents 
a therapeutic opportunity to target RAD52 activity in BRCA-deficient tumors [56, 58, 60, 
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63, 102]. For homologous recombination, breaks are initially processed to produce single-
stranded DNA tails that are then bound by RPA. The PPI of RAD52 with RPA is extensive 
and essential for RAD52 activity in the subsequent steps of repair [75, 79, 103]. Plate and 
co-workers demonstrated by mutational analysis that the ability of RAD52 to form repair 
foci required the RPA-binding domain [78]. Since the structure of the RAD52:RPA PPI is 
unknown, the FluorIA was developed using full length proteins and designed to screen for 
SMIs of the RAD52:RPA PPI in an unbiased manner. The application of this protocol to 
other PPI will support quests to find therapeutic SMIs or modulators targeting cancer or 
other pathological conditions. 
2.3. Materials and methods 
2.3.1. Protein expression and purification. The plasmid for full-length RPA (Figure 
2.1A) in pET29a vector, a gift from Dr. Marc Wold, was transformed into Rosetta2(DE3) 
Escherichia coli with chloramphenicol and kanamycin selection. A single colony was 
inoculated into 5 mL starter culture and grown with selection for 6-8 hours at 37 ºC. Large 
cultures were made by inoculating 1 mL starter culture into 2 L sterilized LB with 
antibiotics in 4 L flasks and incubating at room temperature or 37 ºC overnight without 
shaking. The following day, the cultures were incubated at 37 ºC with shaking and induced 
with 0.5 mM isopropyl-β-D-l-thiogalactopyranoside (IPTG) at an A600 of 0.6-0.8. After 3 
hours, cells were collected by centrifugation at 8,500 xg for 20 min. Pellets were divided 
into 5 gram portions and stored frozen at -20 ºC.  
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Figure 2.1 Domain maps of proteins used in this study. (A) RPA, (B), RAD52(1-
303), (C) Full length RAD52 tagged with 6x His EGFP. Structured domains and 
flexible linkers indicated as thick and thin boxes respectively.  
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Each RPA cell pellet was thawed and resuspended in 25 mL of HI-0 buffer [30 mM 
HEPES pH 7.8, 0.25% inositol, 0.25 mM EDTA, and 1mM dithiothreitol] with 500 mM 
sodium thiocyanate (NaSCN) plus 250 μL of protease inhibitor cocktail (PIC, Sigma, Cat. 
#P8849) before lysis using an Emulsflex-C3. Lysate was clarified by centrifugation at 
45,000 xg for 30-45 min. The NaSCN content was reduced by either dilution or dialysis 
against HI-0 buffer and then filtered through a 0.45 μm filter. All chromatography steps 
employed HI-0 with varying salts. First the lysate was applied to a HiTrap Blue HP column 
(5 mL, GE Life Sciences # 17-0412-01) and washed For 5 CVs with 800 mM KCl followed 
by 5 CVs with 0.5 M NaSCN and then eluted with 1.5 M NaSCN into 1 mL fractions. The 
NaSCN content was reduced by either dilution or dialysis against HI-0 buffer and then 
applied to a hydroxyapatite column (3 mL, BioRAD # 157-0040) and eluted in a 25 CV 
gradient of 0-75% 160 mM NaPO4. The column was cleaned by washing with 2 M KPO4 
in HI-0 after each use. RPA fractions were pooled and diluted with 4 volumes HI-0 before 
polishing with a monoQ anion exchange column (1 mL, GE Life Sciences # 17-5166-01). 
RPA was eluted in a 25 CV gradient of 0-100% 1 M KCl. Throughout the purification 
procedures described above, fractions were examined by 10% polyacrylamide gel 
electrophoresis (SDS-PAGE) with Coomassie stain (Figure 2.2). A NanoDrop1000 was 
used to measure concentrations using a molecular weight of 110 kDa and ɛ280=87.2 M-1cm-
1. Finally, purified RPA was stored at -20 °C in 500 mM KCl in HI-0 with 30% glycerol 
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Figure 2.2 Proteins used in FluorIA. SDS-PAGE gel of the purified 
proteins. 
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The RAD52(1-303) (Figure 2.1B) in pET28b plasmid was a gift from Dr. Min Park. It 
has a 6xHis tag on the C-terminus that is not cleavable. Transformation was done into 
Rosetta2(DE3). Expression and growth were the same as described for RPA with the 
exception of allowing large cultures to cool in an ice bath for 30 min before inducing with 
IPTG. Cultures were then transferred to a pre-chilled shaker at 18 ºC for 15-18 hours. 
Pellets were processed in the same manner described above. 
A thawed RAD52(1-303) cell pellet was resuspended in 25 mL of buffer A [50 mM 
Tris-HCl pH 7.8, 300 mM KCl, 2 mM β-mercaptoethanol (β-ME), 10 mM imidazole, and 
10% glycerol] with 250 μL of PIC and lysed. Clarified and filtered lysate was then loaded 
onto a HisTrap FF column (5 mL, GE Life Sciences). The protein eluted with a 25 CV 
gradient to 1 M imidazole in buffer A. Eluted fractions were pooled and dialyzed against 
heparin buffer (50 mM Tris-HCl pH 7.5, 200 mM KCl, 2 mM β-ME, 0.5 mM EDTA, and 
10% glycerol). The dialyzed protein was loaded onto a HiTrap Heparin HP column (5 mL, 
GE Life Sciences) and eluted with a 25 CV gradient to 1 M KCl in heparin buffer. The 
recovered protein was dialyzed overnight into a storage buffer (20 mM HEPES pH 6, 400 
mM NaCl, 100 mM KCl, 1 mM EDTA, 2 mM β-ME, and 10% glycerol). The protein was 
stored frozen with 30% glycerol. A NanoDrop1000 was used to measure concentrations 
using a molecular weight of 34.6 kDa and ɛ280=20.4 M-1cm-1. Purity of fractions was 
assessed by SDS-PAGE (Figure 2.2).  
Full-length RAD52 tagged with 6X-His enhanced green fluorescent protein (EGFP-
RAD52) (Figure 2.1C and Figure 2.3), in pET28a vector was ordered from GenScript with 
codons optimized for E. coli expression and the overall design is described in the 
29 
 
supplement. BL21(DE3) were transformed and selected with kanamycin. Expression, 
growth, and pellet storage was as described for RAD52(1-303). It is noteworthy that 
overnight growth at 18 ºC was mandatory for protein expression. 
30 
 
EGFP (MW = 29.1 kDa)  
MGSSHHHHHH SSGLVPRGSH MVSKGEELFT GVVPILVELD GDVNGHKFSV 50 
SGEGEGDATY GKLTLKFICT TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK 100 
QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID 150 
FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA 200 
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI 250 
TLGMDELYK  259 
Note, the F64L\S65T EGFP mutations are highlighted in green and the thrombin cleavage 
site is underlined. 
EGFP-RAD52 (MW = 76.2 kDa) 
MGSSHHHHHH SSGLVPRGSH MVSKGEELFT GVVPILVELD GDVNGHKFSV 50 
SGEGEGDATY GKLTLKFICT TGKLPVPWPT LVTTLTYGVQ CFSRYPDHMK 100 
QHDFFKSAMP EGYVQERTIF FKDDGNYKTR AEVKFEGDTL VNRIELKGID 150 
FKEDGNILGH KLEYNYNSHN VYIMADKQKN GIKVNFKIRH NIEDGSVQLA 200 
DHYQQNTPIG DGPVLLPDNH YLSTQSALSK DPNEKRDHMV LLEFVTAAGI 250 
TLGMDELYKG GSGGSGGSGG SGGMSGTEEA ILGGRDSHPA AGGGSVLCFG 300 
QCQYTAEEYQ AIQKALRQRL GPEYISSRMA GGGQKVCYIE GHRVINLANE 350 
MFGYNGWAHS ITQQNVDFVD LNNGKFYVGV CAFVRVQLKD GSYHEDVGYG 400 
VSEGLKSKAL SLEKARKEAV TDGLKRALRS FGNALGNCIL DKDYLRSLNK 450 
LPRQLPLEVD LTKAKRQDLE PSVEEARYNS CRPNMALGHP QLQQVTSPSR 500 
PSHAVIPADQ DCSSRSLSSS AVESEATHQR KLRQKQLQQQ FRERMEKQQV 550 
RVSTPSAEKS EAAPPAPPVT HSTPVTVSEP LLEKDFLAGV TQELIKTLED 600 
NSEKWAVTPD AGDGVVKPSS RADPAQTSDT LALNNQMVTQ NRTPHSVCHQ 650 
KPQAKSGSWD LQTYSADQRT TGNWESHRKS QDMKKRKYDP S  691 
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Figure 2.3 Details of EGFP and EGFP-RAD52 expression plasmids and proteins.  All 
expression plasmids were made by Genscript®. Codons were optimized for expression in 
Escherichia coli.  Enhanced green fluorescent protein (EGFP) was cloned into the pET28a plasmid 
using the NdeI site so that a thrombin cleavable, 6X His tag was placed at the N-terminus.  The NT-
EGFP-RAD52 was cloned into pET28a in a similar manner. For the later construct a disordered 
soluble linker was inserted between EGFP and RAD52. Note, the amino acid sequences with a 
dotted underline are disordered in the EGFP crystal structure (PDB ID 2Y0G).  The soluble 
disordered linker has a double underline and the human RAD52 sequence is highlighted in yellow. 
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Thawed EGFP-RAD52 cell pellets were resuspended in 25 mL buffer B (50 mM 
BICINE pH 9, 300 mM KCl, 200 mM NaCl, 10 mM imidazole, 10% glycerol, and 2 mM 
β-ME) with 250 μL of PIC and lysed. The clarified lysate was loaded onto a HisTrap 
column and eluted in a 25 CV gradient to 1 M imidazole in buffer B. Keeping the lysate 
and buffers ice-cold throughout was necessary to prevent the loss of the EGFP tag from 
the protein. A NanoDrop1000 was used to measure concentrations using a molecular 
weight of 76 kDa and ɛ280=63.0 M-1cm-1. The protein product was verified by SDS-PAGE 
gel (Figure 2.2). The protein solution was then mixed with 30% glycerol and stored at -20 
ºC.  EGFP-RAD52 must be made fresh the week of HTS. 
A plasmid of 6xHis-tagged EGFP in pET28a vector was ordered from GenScript with E. 
coli optimized codons and transformed into BL21(DE3) with kanamycin selection. 
Expression, growth, and pellet storage was as described for RAD52(1-303). EGFP cells 
were resuspended in 25 mL buffer C (50 mM BICINE; pH 9, 20 mM imidazole, 200 mM 
NaCl, and 2 mM β-ME) with 50 μL of PIC and lysed. The lysate was loaded onto HisTrap 
column and eluted with 25 CV gradient up to 500 mM imidazole in buffer C. The tag was 
removed by thrombin digestion to give pure EGFP (Figure 2.2). 
2.3.2. FluorIA procedure. The first step of the FluorIA procedure is to prepare RPA 
plates (Figure 2.4 top left). Purified RPA, diluted to 0.2 µM with milli-Q water, is 
dispensed by Multidrop Combi (ThermoScientific) to uniformly fill each well of a 384-
well, high-binding, “MaxiSorp”, black Plastic, flat bottom, opaque microtiter plate 
(Thermo Fisher Scientific, #460518) to 75 µL volume. Centrifugation at 500 xg for a few 
seconds prevents air bubble formation and evenly coats the well. Plates are then 
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incubated on an orbital shaker for 1 hour at room temperature, then excess protein 
solution is decanted by flicking plates upside down several times and striking repeatedly 
against a pad of paper toweling to remove residual liquid. Unbound RPA is removed by 
two washes, 85 µL per well, using wash buffer (1X PBS with 0.2% Tween-20) with 
elimination of residual liquid after each washing step as described above. Freezing-
blocking buffer (5% milk in 1X PBS with 30% glycerol) is then dispensed at 85 µL per 
well and plates briefly centrifuged. Following a 10 min room temperature incubation on 
an orbital shaker, each plate is sealed with an aluminum adhesive sheet (Thermo 
Scientific, Cat. # AB-0626) and stored in the -20 ºC freezer until use. Typically, we can 
make 60 to 80 RPA plates per day. 
On a screening day, the desired number of RPA plates are thawed for 1 hour at room 
temperature. Then the aluminum seal is removed, and the freezing-blocking buffer 
decanted. The plates are washed once and decanted. Two protein mixtures are prepared 
on the day of the screen: mixture-A is 1.33 µM RAD52(1-303) with 2.67 µM EGFP-
RAD52 in 1xPBS-5% milk, and mixture-B is 2.67 µM EGFP-RAD52 alone in 1xPBS-
5% milk. In the optimized protocol 75 µL of each protein mixture is used per well. 
Mixture-A is dispensed into one column per plate to serve as a positive control (known 
inhibitor, Figure 2.4, column 21) while mixture-B is dispensed into all wells that receive 
a test compound from the chemical library or buffer only control. A column is reserved 
for 1xPBS-5%-milk as a buffer blank (Figure 2.4, column 22). At this point, the RPA 
plates are ready to receive compounds from a chemical library. A Biomek F/X liquid 
handler (Beckman Coulter LifeSciences) automated the transfer of test compounds from 
a chemical library source plate into the wells of a RPA plate. After test compound 
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addition, RPA plates are centrifuged at 500 xg for a few seconds. The plates are covered 
with aluminum foil and placed on an orbital shaker for 1 hour at room temperature. Then 
three washes are performed to remove unbound chemicals and excess protein before the 
relative fluorescence (RFU) is measured using a POLARstar OPTIMA plate reader 
(BMG LABTECH) on emptied plates at an excitation/emission (for EGFP) of 485/520 
nm at 2500 gain setting. Plates must be read decanted as reading them with liquid present 
increased variation in the data. 
35 
 
 
  
36 
 
  
Figure 2.4 HTS FluorIA procedure diagram and representative data. 
Columns 1-20 are the screen of a chemical library. Column 21 is inhibited 
with RAD52(1-303) control and column 22 is buffer control. Column 21 is 
the PC and column 22 is the NC in wquation 2. Well K18 is a hit. 
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2.3.3. Strategy for screening libraries of compounds. For large library screening, a 
single concentration is used (e.g. 100 μM). Plates are repeated to eliminate false hits. 
Then triplicate repeats further verify hits. With this strategy, it is possible to screen up to 
10,000 compounds per day with two workers.  
2.3.4. Statistical analysis. A screening window coefficient (denoted Z-factor) is used to 
assess the quality of the signal throughout screen optimization and application.  
 Z = 1 −
3SD of sample+3 SD of control
|mean of sample−mean of control|
 (1) 
Here, the assay value in the absence of potential inhibitor is the “sample” while the 
“control” is the value in the presence of the known competitive inhibitor RAD52(1-303). 
In some early pilot assays EGFP was the control. If 1 > Z ≥ 0.5 then the separation band 
between the sample and control is large enough and the assay is considered excellent. 
Candidate SMI hits are identified as follows: On each screening plate, the average value 
of a designated column containing no potential inhibitors and buffer only is a negative 
control (NC). The average value of a column containing the known inhibitor RAD52(1-
303), is the positive control (PC). Then 
 Xhit = (NC −
NC−PC
2
) 100 (2) 
A SMI is considered a hit if Xhit is 50% or lower (Figure 2.4, shown as light orange in 
well K18). A value of 50% is used for this example because the RAD52:RPA PPI under 
study probably involves two binding surfaces and a hit might bind to only half of the 
uncharacterized surface. The hits are also three standard deviations below the NC. 
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2.4. Results and discussion 
Previously, we used an ELISA-based method that required antibodies and 
chemiluminescence for detection to analyze the domains of RPA interaction on RAD52 
and vice versa.[103]. This method worked well for biochemical type assays but is too 
cumbersome, expensive, and uses far too many wash steps to be practical for HTS. The 
FluorIA is a new approach that obviates the need for antibodies, thus avoiding problems of 
non-specificity, and detects PPI simply with purified proteins with a minimal number of 
steps and low cost. Here, purified RPA is directly bound to a black, high-binding microtiter 
plate and the PPI detected with RAD52 tagged with EGFP (Figure 2.1C and Figure 2.3). 
An increased relative fluorescent unit (RFU) is detected when EGFP-RAD52 is added to 
RPA (Figure 2.5). A similar response is not detected with the EGFP tag alone indicating 
the interaction is between RPA and RAD52 not between RPA and the EGFP tag. Z-factor 
analysis with EGFP tag as a control helped us select minimal protein levels that gave an 
optimal response (Figure 2.5). The best Z-factor value along with lower variation in 
replicates was obtained for 20 pmol of EGFP-RAD52 per well added to 10 pmol of RPA. 
Despite higher signal value with 40 pmol EGFP-RAD52, we use 20 pmol concentration 
for HTS as it gives a consistently good Z-score in repeats and meets the goal of lowering 
the cost of reagents.  We tested pilot assays with 25 μL/well or 75 μL/ well reaction (data 
not shown). A 75 µL volume gives the best signal as it filled the small 384-well without 
overflowing and allowed RPA to bind the flat bottom as well as the walls of the well for 
increased signal. As optimization progressed, we increased the amount of RPA to 15 pmol 
to ensure sufficient RPA per well after multiple washing and handling procedures. 
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Excellent Z-factors greater than 0.5 are obtained in the FluorIA mainly due to the low 
standard deviation of the screen and large difference between PC and NC. 
Temperature is another factor to consider. To see the effect of temperature, two plates 
were incubated at 22 °C and 28 °C individually (Figure 2.6). The results suggest that it is 
best to perform the screen at room temperature and to watch the thermostat. Higher 
temperature fluctuations probably result in detachment of the bound RPA from the wells 
resulting in lower signal. Therefore, the FluorIA is conveniently conducted at room 
temperature. 
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Figure 2.5 Optimization of protein levels per well. Z-factors were 0.39, 0.73 and 0.66 for 
10, 20, and 40 pmol respectively. 
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Figure 2.6 The effect of temperature on FluorIA. The reaction 
was done at 22 ºC and 28 ºC. 
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Further development of the assay required the use of a robust known inhibitor for the 
statistical analysis of each plate and hit identification. Previous work by our group shows 
that RAD52:RPA electrostatic interaction can be disrupted by increased salt 
concentration.[103] Therefore, we diluted the EGFP-RAD52 with a range of 0-1 M KCl 
before adding it to the RPA plate. Consistent with our previous findings, inhibition was 
evident by a progressive decrease in fluorescence signal with increased salt concentration 
(Figure 2.7A). However, it was evident that a much larger salt concentration was required 
to achieve the desired baseline inhibition. The possibility of salt interfering with the 
chemical libraries motivated us to search for an alternative inhibitor. 
Previously, we demonstrated that the primary interaction sites for RPA on RAD52 are 
within residues 193-303 [103].  Also RAD52(1-303), which has intact RPA binding 
domains but is missing the remaining 115 residues at the C-terminus, exhibits a slightly 
higher RPA binding activity compared to full length RAD52 [103]. Interestingly, Plate and 
coworkers reported an enhanced repair activity for a yeast Rad52(1-307) construct 
compared to full-length Rad52 [78]. Accordingly, RAD52(1-303) inhibits the FluorIA by 
competing with EGFP-RAD52 for RPA binding. In a pilot screen, 20 pmol of EGFP-
RAD52 was incubated with increasing concentrations of RAD52(1-303) in the RPA plate 
(Figure 2.7B). At a molar ratio of 1:1, 50% inhibition is observed and with increased 
concentration of RAD52(1-303), baseline inhibition is achieved. Therefore, 100 pmol of 
RAD52(1-303) is used as a known inhibitor (positive control) in the FluorIA.  
At this juncture, it was necessary to assess the resilience of the FluorIA readout signal 
with the added challenges of a HTS. Typically, compounds in chemical libraries are 
dissolved in 100% DMSO and that could be detrimental to the integrity of purified proteins, 
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the main components of the FluorIA. We plan to limit the final concentration of DMSO to 
no more than 5% per reaction well in HTS. To see any effects, different amounts of DMSO 
were added with EGFP-RAD52 before incubating in the RPA plates (Figure 2.8). 
Fortunately, up to 5% DMSO has no significant effect on the FluorIA signal.  
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Figure 2.7 Known inhibitor. Finding suitable competitive 
inhibitors to serve as control (A) KCl or (B) RAD52(1-303). 
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Figure 2.8 Testing the effect of DMSO. DMSO was added up to 5% in the 
FluorIA reaction. 
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The parameters defined above provide the essentials for an HTS assay, namely, 
sensitivity, reliability, and homogeneity. Subsequent work creates a successful process for 
screening large libraries with minimum time and maximum cost efficiency. Assay steps 
need to be minimized and automated for simplicity and speed. The storage of assay plates 
over various times and to optimize proper storage conditions was addressed. Once the 
storage condition in 30% glycerol at the blocking step was found to be optimal, three 
different RPA plates were tested after freezing overnight to assess plate-to-plate variability 
(Figure 2.9A). As no difference was detected, we conducted the freezing test for up to two 
weeks and freezing did not lead to change in signal output (Figure 2.9B). Thus, making the 
RPA plates ahead of time and freezing them provides a convenient stopping place in the 
FluorIA protocol. Also, having the RPA incubation, washing, and blocking steps done 
ahead significantly mitigates the number of steps to be done on the day of HTS, reduces 
the risk of costly errors and allows for screening of several thousand chemicals a day. The 
case is not the same with EGFP-RAD52. The EGFP signal diminishes with time stored 
(Figure 2.9C). EGFP-RAD52 must be freshly purified the week of the screen. On a HTS 
day, it is critical to perform a test plate of all proteins and buffers to test activity and Z-
factor before committing to a long day of screening.   
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Figure 2.9 Reagent shelf life. (A) RPA plate variation with three different RPA 
assay plates prepared, sealed and frozen overnight. (B) Effect of short term freezing 
on RPA plates. (C) Effect of freezing on purified EGFP-RAD52 signal. For part C, 
nonbinding plates and gain setting of 1000 was used. 
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The final optimized parameter is the buffer system. For most of the pilot optimization 
screens, an EDTA-containing buffer system was used. By exploring other buffer systems 
we found that 1x PBS gives a larger change between positive and negative controls 
contributing to the statistical quality of the assay (Figure 2.10).  
PPIs are important in biological processes as well as pathology. Here we demonstrate 
how the simple FluorIA protocol can be used to find SMIs that disrupt the RAD52:RPA 
interaction. Future HTS of SMI libraries will follow the full FluorIA optimization 
described here. The well-coordinated flow of the FluorIA and analysis makes it possible 
to screen up to 10,000 compounds per day. FluorIA is applicable to PPI where the 
purified protein maintains activity. FluorIA is not restricted to screening SMIs and is 
suitable to test aptamers as well.   
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Figure 2.10 Optimal buffer choice. Testing EDTA and 1x PBS 
buffers in FluorIA. 
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2.5. Conclusion 
PPI take central importance in biological processes and their pathological changes. 
Early developments of HTS were based on targets other than PPI.  We now realize that 
modulating PPI with small molecule is not only possible but advantageous in the quest of 
targeted therapeutics.  
We developed FluorIA to find SMIs that can disrupt RAD52:RPA interaction. Following 
full optimization, we were able to do an unbiased screen of three large libraries of 
potential SMIs. The flow of the HTS and analysis was well coordinated, and it was 
possible to screen up to 10, 000 compounds per a screen day.  
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Chapter 3 
Characterizing the RAD52:RPA complex 
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3.1. Abstract 
RAD52 interaction with RPA constitutes a crucial step in its known and newly 
emerging roles in DNA damage repair. RPA’s main function in the cell is to protect 
ssDNA strands and relax DNA secondary structures during the process of normal DNA 
replication or repair. RAD52 plays a role in repair processes such as HRR, SSA, or 
break-induced repair processes, RAD52 requires direct interaction with the RPA 
occupying the ssDNA at the damage site for activity. Recently, there is an increased 
appreciation for RAD52’s role in the maintenance of tumorigenesis. The molecular and 
dynamic details of RAD52:RPA interaction are of great interest with increasing efforts to 
target RAD52 DNA repair activity to kill tumor cells. Here we use the FluorIA we 
developed along with kinetic and thermodynamic measurements to investigate the 
RAD52:RPA interacting. The interaction of RPA with RAD52 has dissociation constant  
of 0.1 μM and the interaction appears strong enough to be physiologically relevant and 
has the potential to be a therapeutic target.   
3.2. Introduction 
HRR is one of five major DNA repair pathways that make it possible for cells to 
combat DNA lesions encountered during the course of replication [104]. HRR is a 
specialized and accurate repair for DNA DSBs, a type of DNA damage that is of a 
particular significance in cancer [105]. Not surprisingly, PPIs in this repair pathway are 
of central importance in tumorigenesis development and potential candidates in targeted 
therapy [106, 107].  
RPA is a heterotrimer composed of three subunits and binds ssDNA intermediates of 
DNA metabolism and repair processes [77, 108]. The dynamic nature of this binding 
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stretches beyond protection into specific and essential interaction with protein partners to 
ensure the efficiency of these processes [109].  RAD52 is an important protein partners 
that functions in HRR, SSA, BIR, RNA-templated DSBs repair [57, 66, 75]. With RPA 
being an early responder, when RAD52 seek to repair damaged DNA, RPA had already 
proceeded to the site making this PPI crucial in initiating the repair processes. RPA 
interaction is reported to either dictate or stimulate RAD52 repair activity. Plate and co-
workers demonstrated that there is a requirement for direct interaction with RPA for 
Rad52 to carry out its role in HR repair [78]. Moreover, in the newly characterized role 
for RAD52 in RNA-templated DSBs repair, the addition of RPA to the reaction clearly 
stimulated the repair activity [72].  
RAD52 and RPA proteins received great interest from researchers due to their 
significant roles in normal and pathological processes. Flexible linkers connecting the 
three subunits of RPA hindered efforts for a full structural view of the protein [110-116], 
while RAD52 was revealed as a ring structure using electron microscopy and X-ray 
crystallography [117-120]. The RAD52 ring was predicted by Singleton to provide a 
positively charged groove as a binding pocket for ssDNA [120]. This structural 
knowledge along with emerging understanding of RAD52 role in tumorigenesis, 
motivated the search for therapeutic agents that can disrupt the RAD52 ring to target its 
activity [62, 74]. Our past data showed that conformational changes offered by RPA 
interaction dictate the activity of RAD52 in DNA repair. Namely, we found that in the 
absence of RPA, RAD52 existed in rings and aggregates of rings. However, monomer 
RAD52 purified in a stable complex with RPA-ssDNA. Additionally, we found that RPA 
alone was capable of promoting the breakage of the RAD52 ring structure. These 
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findings motivated our interest in the RAD52 monomers as the potential active form in 
DNA repair [79, 103].  
Here, we aim to characterize the RAD52:RPA complex and validate its candidacy for 
targeted therapeutics. FluorIA, was used to delineate the RPA-binding domains on 
RAD52. Using the same method, the RAD52 interaction surface on RPA, based on 
previously reported NMR data, was investigated [121]. SPR was then utilized to study 
the affinity of RPA interaction with full-length and truncated mutants of RAD52. Finally, 
ITC analysis was used to validate our SPR findings for the full-length proteins.   
3.3. Materials and methods 
3.3.1. Proteins purification.  
RPA purification was done as described in Chapter 2. To make the ssDNA:RPA 
complex, RPA was mixed with an excess molar concentration of a 25-mer 
oligonucleotide (GCTAGCTCAATTCATCGACAAACCTT) (1:1.1 ratio) that was 
synthesized and reconstituted as described by Deng and coworkers [79]. The complex 
was incubated on ice for one hour before purification using size exclusion column (see 
above) with 300 mM KCl in HI-0 buffer described in Chapter 2. Fractions containing the 
complex were selected guided by the 260/280 ratio read by NanoDrop1000 and purity of 
the sample as judged by SDS-PAGE (Figure 3.1A).   
The 6xHis-tagged RPA was expressed using the pET-Duet system. The plasmids 
were made by GenScript with codons optimized for E.coli. RPA70 was cloned into 
multiple cloning site 2 (MCS2) of pCOLA Duet-1 with kanamycin resistance. His-
RPA14 and RPA32 were cloned into MCS1 and MCS2, respectively, in pACYC Duet-1 
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plasmid with chloramphenicol resistance. These were transformed into BL21(DE3) E.coli 
with chloramphenicol and kanamycin selection. The expression procedure was as 
described for RPA in Chapter 2. A 5 g cell pelleted His-tagged RPA was resuspended in 
25 mL of buffer A with 250 μL of PIC and lysed. Clarified and filtered lysate was then 
loaded onto a HisTrap FF column (5 mL, GE Life Sciences). The protein eluted with a 25 
CV gradient to 1 M imidazole in buffer A. The purity of the protein fractions were 
examined by 10% SDS-PAGE (Figure 3.1B).   
6xHis tagged RPA32(172-270), also known as the winged-helix-loop-helix region 
(wHLH) (MW 9.4kDa), a generous gift from Dr. Marc Wold and was transformed into 
Rosetta2(DE3) with chloramphenicol and kanamycin selection. Protein expression was as 
described for RPA in Chapter 2. For purification, a RPA32(172-270) pellet was thawed 
and resuspended in buffer D [10 mM NaPO4 pH 7.5, 150 mM NaCl, 10 mM imidazole, 
and 2 mM β-ME] with 250 μL of PIC and lysed. Clarified lysate was filtered through a 
0.45 μM filter then loaded onto a His Trap FF column (1 mL, GE Life Sciences). The 
protein eluted with a 25 CV gradient to 1 M imidazole in buffer E. Pooled fractions were 
diluted with 4 volumes of buffer F [20 mM NaPO4, pH 7.5, 50 mM NaCl, 2 mM β-
mercaptoethanol (β-ME), 0.5 mM EDTA] and polished using a monoQ anion exchange 
column (1 mL, GE Life Sciences # 17-5166-01). The protein was eluted in a 25 CV 
gradient of 0-100% 1 M KCl in buffer F. Since 6xHis-RPA32(172-270) has no 
tryptophan, a UV absorbance at 210 nanometers was necessary for detection of protein 
fractions. Fractions were also examined by 12% SDS-PAGE (Figure 3.1C). The 
bicinchoninic acid assay (BCA assay) was used to measure protein concentration.  
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The His-tag was removed from a portion of the purified wHLH by thrombin digestion 
(10 U/mg tagged protein) to use it in SPR as an analyte over RAD52-bound to NTA chip. 
Thrombin, loose His tags, and still-tagged protein were removed from the digestion 
mixture by adding benzamidine resin (removes thrombin) and nickel resin (removes His). 
Tagged and detagged wHLH were examined by 12% SDS-PAGE (Figure 3.1C). 
RAD52(1-418), RAD52(1-303), and RAD52(1-212) all in in pET28, were 
transformed into Rosetta2(DE3) E.coli with chloramphenicol and kanamycin selection. 
RAD52 (168-306) and EGFP-RAD52(1-212) in pET28a (GenScript) were transformation 
in BL21(DE3) E.coli with kanamycin selection. Expression and purification for all these 
RAD52 constructs was done in the same manner described for RAD52(1-303) in Chapter 
2. Purification of, RAD52 (168-306) and EGFP-RAD52(1-212) expression and 
purification included an additional size exclusion (Superdex 200, HiLoad 16/60, GE Life 
Sciences) purification step preceded by an overnight dialysis into a high-salt buffer (20 
mM HEPES pH 7.5, 400 mM NaCl, 100 mM KCl, 1 mM EDTA, 2 mM β-ME, and 10% 
glycerol). RAD52 (168-306) sequence contains no tryptophan so a UV absorbance at 210 
nm was necessary for detection of protein fractions during purification. Fractions were 
examined by 10% SDS-PAGE with Coomassie stain (Figure 3.2). The RAD52(257-274) 
peptide was purchased (GenScript). Peptides was diluted to 10 mM in nuclease-free 
water and stored frozen at -20 °C 
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Figure 3.1 Purified proteins in SDS PAGE gels. (A) Fractions of 
ssDNA: RPA, (B) 6xHis- tagged on RPA14 subunit next to untagged RPA14, 
(C) RPA32(172-270) with or without 6xHis tag 
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Figure 3.2 SDS PAGE gels shown His-RAD52(168-306). 
67 
 
 
3.3.2 Isothermal titration calorimetry procedure and sample preparation. ITC 
titrations were performed on an iTC200 (Malvern Instruments Inc. Northampton, MA). A 
total of 15 injections of RPA with concentration 150-300 µM were performed into a 0.2 
mL reaction cell containing a solution of RAD52 with concentration about ten times 
smaller than the titrant. The total injection volume was 37 µL with individual injection of 
2 or 3 µL. All experiments were carried out at room temperature and mixing rate 1000 
rpm. Reaction heats were measured by integration of the area of the injection curve, 
corrected for the dilution heat of the titrant, and normalized by the moles of titrant added. 
Experiments with a low range of RPA concentrations (150-170 µM) were performed to 
measure the heat of reaction directly in initial steps of the titration. The average of 4-5 
injections at concentrations less than saturation provides the reaction enthalpy, ΔHITC. 
The resultant thermograms were analyzed using single set of binding sites model of the 
MicroCal LLC software based on the Levenberg-Marquardt non-linear least square curve 
fitting algorithm to provide binding affinity, binding stoichiometry and enthalpy of 
binding (ΔH°). The binding free energy (ΔGº) and the entropic contribution to binding 
were then calculated using standard thermodynamic relationships. 
Purified RPA and RAD52 were first concentrated separately using spin concentrators 
(30,000 and 3,000 MWCO respectively). RPA and RAD52 were then dialyzed separately 
against 1x PBS buffer with 1 mM EDTA and 2 mM βME overnight followed by a second 
round the next day for a minimum of three hours. Concentrations of the proteins were 
checked before and after dialysis using a NanoDrop1000 applying ɛ280=87.2 M-1cm-1 for 
RPA and ɛ280= 20.4 M-1cm-1 for RAD52.  
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3.3.5. Surface plasmon resonance analysis. OpenSPR instrument (Nicoya 
Lifesciences,) as well as Biacore 3000 (Biacore AB, Uppsala, Sweden) were used. 
OpenSPR utilizes gold nanoparticles instead of traditional gold SPR films for the sensor 
chip. Also the OpenSPR instrument uses LSPR that differs from traditional SPR in that it 
employs readings of absorption of the sensor substrate chip.  
For the OpenSPR analyses, sensor chips (SEN-Au-100-12-NTA) was installed and 
Nickel labeled according to manufacturer’s recommendations. Based on experimental 
pilot tests, 25-50 μg/mL of the His-tagged ligand could be bound on a chip. When the 
ligand was a RAD52 construct, we used the HBS-PE running buffer [10 mM HEPES pH 
7.4, 150 mM NaCl, 3.4 mM EDTA, and 0.005% Tween20] at a higher salt concentration 
of (500 mM NaCl) to ensure best binding and activity. To analyze multiple analyte 
concentrations, multiple two or three-fold dilutions were made typically: 900, 300, 100, 
33, and 11 nM along with a zero (HBS-PE buffer only) condition. HBS-PE buffer at 150 
mM NaCl buffer was used as the running buffer in the system throughout the analyte 
binding and regeneration processes. The salt concentration of 150 mM for ligand-analyte 
binding was based on our previous work in making the RAD52:RPA complex [79]. 
Resulting data were processed using TraceDrawer software provided by Nicoya. Each 
experiment was repeated several times and repeats with the best fit Chi2 value were 
selected for average, standard deviation and variance calculations. 
Interaction analyses of full-length RPA and RAD52 were also done using a Biacore. 
For this kinetic analysis, amine coupling with a CM5 sensor chip was performed. RAD52 
was chosen to be the ligand to bind the carboxymethyl groups containing CM5 chip 
while RPA was flowed over as the analyte. 
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A 20 mM MES buffer (pH 5.5) was chosen for immobilization of ligand while 1x 
PBS containing 0.005% Tween was used for running the analyte. Then 10 mM 
glycine/NaOH (pH 10) was used for regeneration. The CM5 used chip used 
preconditioned with two short pulses of 50 mM NaOH, 100 mM HCl and 0.5% SDS. To 
prepare for ligand binding, individual ligand flow channels were activated with a mixture 
of 1-ethyl-3-[3-dimethylaminopropyl carbodiimide hydrochloride) (0.2 M) and sulfo-N-
hydroxysuccinimide (0.05 M). RAD52 (5-20 μg/mL) was prepared for immobilization in 
20 mM MES buffer (pH 5.5). Ethanolamine-HCl was used to block the remaining excess 
ester groups. The immobilization process resulted in the coupling of RAD52 at a density 
of 1200 RUs (an arbitrary response unit which corresponds to 1 pg/mm2). 
Analyte buffer replaced the immobilization buffer and a series of RPA dilutions were 
prepared for programed injections over the chip. Activation, regeneration, and blocking 
solutions were provided by BIAcore. All data were collected at 25 ºC and evaluated using 
BIAevaluation software (version 3.0). Out of the several experimental repeats, two are 
selected for their lowest Chi2 values of 2.1 and 6.6. 
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3.4. Results and discussion 
3.4.1. Analysis of reported RPA-binding domains on RAD52. Min Park used GST-
pull down studies to identify that the RAD52 region which mediates RPA interaction was 
located within the basic region composed of residues 221 to 280 [122]. Plate and 
colleagues used yeast Rad52 in a series of mutational and biochemical studies to identify 
that RPA is able to interact with Rad52(169-260) (yeast Rad52 numbering) [78]. None of 
the studies mentioned above or others can exclude the possibility for the existence of 
additional RPA-interaction domains on RAD52.  
Previously, our group estimated that the interaction site for RPA is within the RAD52 
region encompassing residues 193-303 by ELISA analysis using different RAD52 
constructs and RPA domains [103]. Interestingly, RAD52(1-303) and RAD52(218-418) 
showed slightly higher binding activity than full-length RAD52 [103]. These results lead 
our curiosity to find out if this binding activity is due to an additional RPA binding site in 
the N-terminus besides the known binding domain in the C-terminus (residues 221 to 
280). 
We used FluorIA to analyze the competitive binding capacity of RAD52(1-303) and 
RAD52(1-212) versus EGFP-RAD52. 20 pmol of full length EGFP-RAD52 was mixed 
with 100 pmol of either RAD52(1-303) or RAD52(1-212) to incubate with RPA.  The 
results shown in Figure 3.3 suggest that the RAD52(1-212) can compete for RPA binding 
with full length EGFP-RAD52 albeit less strongly than observed with RAD52(1-303). To 
explore this further, we tested direct interaction of RPA with EGFP-RAD52(1-212) and 
the results depicted in Figure 3.4 suggest binding activity to RPA. 
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Figure 3.3 Competitive binding in FluorIA. A) SDS-PAGE gel shown full-length RAD52(1-418) to 
the left of the molecular weight marker, RAD52(1-303), and RAD52(1-212). B) FluorIA reaction in which 
20 pmol of EGFP tagged full-length RAD52 is incubated with RPA alone or with a 100 pmol of unlabeled 
RAD52(1-303) or (1-212) to compete with EGFP-RAD52 for RPA binding. Reduction in RFU signal 
signifies more binding activity of the unlabeled RAD52 construct.  
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Figure 3.4 RAD52(1-212) binding to RPA. A) SDS-PAGE gel shown left to right, EGFP-tag, N-
terminal EGFP-tagged full-length RAD52(1-418), and N-terminal EGFP-tagged RAD52(1-212). B) 
FluorIA reaction in which 20 pmol of EGFP tagged full-length RAD52, EGFPRAD52(1-212), or EGFP 
tag are incubated with RPA. Decreasing RFU signal signifies less binding activity as guided by baseline 
signal of EGFP tag alone with RPA. 
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Further work is needed to dissect the role of each of these two RPA-binding domains 
in the DNA “hand-off” mechanism during the repair process but most importantly, this 
information is vital when a therapeutic inhibitor of RAD52 interaction with RPA is 
selected.  
3.4.2. Surface plasmon resonance. The outcome of our FluorIA analysis of 
RAD52:RPA binding activity motivated an investigation to determine the kinetic 
parameters of these interactions. SPR analysis was conducted using the different RAD52 
constructs and the results are summarized in Table 3.1. A representative SPR curves for 
the different complexes each showing the different analyte concentrations are presented 
in figure 3.4. The primary function of RPA is to bind ssDNA and this complex provides 
further stability to the RAD52 interaction [79, 115, 123]. SPR analysis confirmed that the 
RPA:ssDNA complex had stronger affinity with RAD52 than RPA alone. RPA 
interaction with RAD52(1-303) was similar to full-length RAD52. More precise 
experimental measurements of EGFP-RAD52(213-418) show similar interaction affinity 
to full-length RAD52 and RAD52(1-303) with RPA. RAD52(1-212) and RAD52(168-
306) interactions with RPA also show similar binding affinities. The interaction of these 
construct is, after all, electrostatic and thus show similar values. The data here disprove 
previously-speculated negative regulation role for the RAD52 C-terminus.  
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Table 3.1. Binding affinities of different RAD52 and RPA constructs. 
Complexa KD (M)b 
wtRPA:wtRAD52 1.9*10-7 (2.0*10-8 S) 
(ssDNA:RPA):wtRAD52 1.1*10-7 (1.5*10-8 V) 
wtRAD52:RPA(1-303) 1.7*10-7 (9.2*10-8 V) 
wtRAD52:RPA(1-212) 4.8*10-7 (1.7*10-7 S) 
RPA:EGFP-RAD52(213-418) 2.9*10-7 (1.1*10-7 V) 
RPA:RAD52(168-306) 3.2*10-7 (1.2*10-7 S) 
RAD52(257-274): RPA 7.3*10-6 (7.7*10-13 V) 
RAD52(257-274):RPA32(172-270) 4.6*10-6 (1.6*10-7 V) 
RPA32(172-270)RAD52(1-303) 1.2*10-9 (3.9*10-19 V) 
a For the complexes, the protein on the left is the analyte and the protein on the right is the ligand 
and attached to the chip via His tag. 
b The parentheses on the in the right-hand columns are the errors estimated from the standard 
deviation (S) or as variation (V) if only two trials were done. 
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Figure3.5 Representative SPR curves. Legend on the right shows different analyte 
concentrations flown over ligand and regenerating in between. Complex names are on the 
top left corner with the analyte shown on the left side of the colon while the ligand is on the 
right hand. 
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It was based on HR activity analyses of different RAD52 truncations, that most of the 
C-terminal half was excluded to obtain a crystal structure with a good diffraction quality 
[119]. To explore this further, we designed a new His-tagged RAD52(168-306) construct, 
which excluded the C-terminus beyond the RPA binding domain and included the linear 
sequence arm known to facilitate oligomerization [119, 124]. The binding affinity of this 
construct of RPA is the same as of RAD52(1-303) and RAD52 (1-212). The results 
further support the idea that a portion of the N-terminal region of RAD52 is involved in 
binding of RPA. Additionally, comparing the KD values of RPA with RAD52(168-306) 
to that with EGFP-RAD52(213-418) in table 3.1, we observe that the interaction affinity 
was not significantly reduced. This information suggests the absence of a domain of 
RAD52 C-terminus that might be negatively regulating the PPI. 
RPA(172-270) is a region which contains a wHLH structure required for DNA repair 
and a site for PPIs [115]. RAD52 is among the interacting partners on this region and its 
interaction affinity was of interest. As our data indicates that RAD52(1-303) contains the 
entire RPA binding sites, interaction with RPA(172-270) yielded a strong binding affinity 
1*10-9 M. This is interesting as affinity was lower when a full RPA trimer (1.9*10-7) 
suggesting that the full-length is offering inhibitory regions that are of importance to the 
dynamic of interaction. Early work by Bochkarev and colleagues in their work showing a 
DNA-binding activity within the RPA32/14 complex, suggested that N- and/or C-
terminus of RPA32 harbor domains that inhibit ssDNA binding. In later structural work 
by the group, suggested that those RPA32 inhibitory domains are near the L45 loop 
known for promoting ssDNA binding and might be affecting its mobility and reducing 
affinity of interaction with DNA [110]. The strong affinity of interaction of RPA32 C-
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terminus with RAD52(1-303) we observed here suggests a regulatory mechanism for this 
domain in supporting PPI and DNA interaction. Further work is needed to understand if 
increase in affinity for RAD52 is an an accompanying event with reduced affinity for 
ssDNA. 
Interestingly, Mer and colleagues carried NMR analysis of RPA(172-270) with 
RAD52(257-274) and found that the exchange between free and bound state of the 
RAD52 peptide was fast on the time scale of chemical shifts, indicating a weak binding 
[121]. The KD of two other protein partners, UNG and XPA, were reported in their study 
to be 1 and 5 µM respectively and RAD52 peptide was speculated to be weaker. We 
measured RPA(172-270) interaction with RAD52(257-274) and obtained a KD of 4.6*10
-
6 M) which is in excellent agreement with their reported KD values.  
We explored the potential inhibitory effect of RAD52(257-274) peptide of 
RAD52:RPA interaction when added as an SMI in FluorIA reaction (Chapter 2). No 
inhibition was observed for up to 100 μM. This suggest that a binding affinity greater 
than 7*10-6 is needed to inhibit the complex. Similar reactions were carried out with other 
RAD52 peptides we designed (detailed in Appendix I) and no inhibition was observed in 
singles or synergy. These results is probably attributed to weaker affinity as found with 
RAD52(257-274) but it is also possible that the peptides probably do not assume a 
structure that mimics the PPI. 
The kinetics of RAD52:RPA interaction was also analyzed with a different SPR 
instrument and method of coupling. Biacore 3000 was used as described, utilizing amine 
coupling technique to immobilize RAD52 on the CM5 chip and conduct kinetic analysis 
with RPA. Out of the several experimental repeats, two were selected for their lowest 
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Chi2 values of 2.1 and 6.6. The average KD value was 7.8*10
-7(±1.3*10-7 V). This KD 
value obtained was close to that obtained from the OpenSPR system (1.9*10-7) despite 
the different instruments and coupling methods employed for immobilization. 
3.4.3. Isothermal titration calorimetry. The thermodynamic parameters for the 
RAD52:RPA interaction were investigated using ITC. A high concentration of RPA 
(150-300 μM) was titrated against about one-tenth concentration of wt.RAD52 to obtain 
the binding isotherms of the reaction (Figure 3.6). Binding was confirmed in ITC but the 
value we obtained was off by one order of magnitude probably due to experimental 
conditions. We further calculated thermodynamic parameters using the exothermic ΔH 
value (Table 3.2). 
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Figure 3.6 ITC profiles for the titration of RAD52 with RPA. The top panel represents a 
sequential injection of RPA into a solution of RAD52 and the bottom panel shows the 
integrated heat data against molar ratio of [RPA] / [RAD52] after correction of heat of dilution. 
Data points were fitted to one site model and the solid line represents the best fit data with 
fixed N=0.5 and fixed ΔH=8.2 kcal/mol.  
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Table 3.2 Thermodynamic parameters for RAD52:RPA interaction. 
ITC experiments K (M−1) ΔGᵒ (kcal/mol) TΔS (kcal/mol) 
RPA on RAD52 
(run #1) 
1.6*105 (2.7*104) -97.7 -89.50 
RPA on RAD52 
(run #2) 
7.0 *105 (1.7*104) -404.5 -396.3 
Two ITC runs are selected (run 1 is shown in Figure 3.5). ΔGᵒ  = -RT*In(K) equation was used 
to calculate ΔGᵒ and this value was used to calculate TΔS according to the equation ΔG = ΔH – 
TΔS and using the average ΔH= -8.188 Kcal/mol 
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3.5. Conclusion 
RAD52 interaction with RPA is a promising candidate therapeutic target. Inhibiting 
RAD52 repair activity can deprive tumors of an important survival and maintenance 
factor. RAD52 activity is guided and dictated by RPA which guards the ssDNA near the 
damage site. It was imperative, therefore, to understand the nature of this PPI.  
Given the formidable nature of both proteins to full structural analysis, we utilized 
multiple techniques by which we moved from global understanding of binding activities 
to detailed calculations of binding affinity and thermodynamic parameters. With this 
information and close examination of available structural information, we developed a 
new understanding for RPA-interacting domains on RAD52.  
Number of important findings were presented here in characterizing RAD52 
interaction with RPA. First, we confirmed previous supposition for the presence of an 
additional RPA-binding domain within the RAD52 N-terminus. Second, our data here 
disperse key aspects that will be of significant value to further investigate domains 
involved in regulating the dynamic process of DSB repair. Our data disproves previously-
speculated negative regulation role for the RAD52 C-terminus as including the rest of the 
C-terminus did not reduce the affinity of interaction with RPA. Further, measurements of 
the C-terminus wHLH region of RPA32 with RAD52(1303) yielded a strong interaction 
affinity, which was reduces when full-trimer RPA was used. This indicates the presence 
of a domain in the RPA trimer that weakens the interaction with RAD52. What is 
interesting about our finding here is that the C-terminus of RPA32 containing the wHLH 
region, was implicated in offering structural dynamics that reduces the affinity of 
interaction with ssDNA. We have yet to understand whether the strong interacting 
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affinity with RAD52 is an accompanying event that supports the hand-off mechanism in 
repair.  
Overall, the measured KD values makes RAD52:RPA interaction a viable target for 
SMIs. The information here will facilitates tailoring the appropriate method to find a 
fitting therapeutic agent that can target this RAD52:RPA with an appropriate affinity and 
selectivity. Moreover, the map and affinity of RAD52 interaction with RPA will guide 
potential pharmaceutical inhibitors or modulators of this interaction.  
New information here includes regions in RAD52(1-212) are important for binding 
RPA. Also, it is clear that there is a large electrostatic component to the formation of the 
complex.  
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Chapter 4 
HTS analysis and identification of potential 
RAD52 inhibitors 
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4.1 Abstract 
RAD52 activity has been shown to support the establishment and maintenance of 
tumors by addressing their most challenging DNA repair problems such as DSBs and 
collapsed replication forks. In HRR-defective cancer cells, RAD52 becomes particularly 
important in providing a backup repair pathway and therefore, holds a promising 
therapeutic value through synthetic lethality. While there has been several published 
SMIs for RAD52, we differ here in our approach by seeking to prevent RAD52 repair 
activity by impairing its interaction with RPA, an abundantly present protein on ssDNA 
at DNA damage sits. RPA meets RAD52 at every junction in the latter’s quest to reach 
damaged DNA. Beyond this obligatory physical interaction, we and others have 
demonstrated that RPA dictates RAD52 recruitment and function in repair. Through a 
HTS using FluorIA, we identified SMIs that inhibited RAD52 interaction with RPA that 
selectively kill HRR-defective cancer cells.  
4.2. Introduction 
DNA damage response and repair have always been at the center of common 
cancer chemotherapeutic and radiotherapy treatments directed to overwhelm repair 
machineries with mounting DNA lesions. Cancer cells often show dependence on unique 
DNA repair pathways due to frequent mutations in repair-related genes or proteins and 
their higher demand for repair to sustain their active division. The evolving avenues in 
targeted cancer therapeutics are not far from these principles, but aspire to zero-in on 
selected factors that are dispensable for normal cells thus sparing them from collateral 
damage [125]. Coupling maladaptive mutations in cancer with pharmacological 
inactivation of another target to induce selective cell death is called synthetic lethality 
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[101]. This approach minimizes side effects that exhaust patients and has the potential to 
lift the roadblocks for the treatment of aggressive subtypes of cancers for which there are 
currently no effective therapies. High-grade serous ovarian and triple negative breast 
cancers, for example, are among the most lethal subtypes characterized by poor 
prognosis, high rate of reoccurrence and metastasis [23, 126]. Many patients with these 
specific subtypes harbor somatic mutations in BRCA1 or BRCA2 contributing to the 
development and progress in PARP inhibitors [49, 127, 128].  
Poly (ADP-ribose) polymerase (PARP) enzymes catalyze polymerization of ADP-
ribose moieties (PARsylation). Serial of PARsylation facilitate the repair of SSBs in 
DNA. Inhibiting this catalytic activity impairs SSB repair and cause the formation of 
DSBs [129]. The exacerbating amount of DSBs is purposefully induced by PARP 
inhibitors to challenge cancer cells. This approach appears to be effective against cancers 
that are defective in HRR [130]. Cross-reactivity among some PARP family members to 
developed inhibitors has unfortunately caused side effects emerged [131]. Also, 
resistance to PARP inhibitors is a problem, so there is a need for additional selective 
treatments for HRR-defective cancers.  
The specialty and high fidelity of HRR for DSBs make it a candidate pathway to look 
for cancer targets as exemplified by the story of PARP inhibitors [8]. Importantly, cells 
with defective BRCA2 or related proteins shows dependency on RAD52 protein to 
maintain functional RAD51-mediated HRR repair activity of DSBs [100]. In fact, other 
RAD52 repair activities such as SSA were reported to increase in BRCA-related defects 
in HRR [69, 71]. These findings helped establish a body of research targeting RAD52 
activity to induce selective killing of BRCA-deficient tumors [60, 62, 74]. 
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New findings about the role of RAD52 in tumorigenesis further qualifies it as an anti-
cancer target [132]. RAD52, for example, is specifically recruited to in break-induced 
repair (BIR) and the restart of collapsed replication forks [66]. Supporting role in the 
establishment and maintenance of tumors, RAD52 expression was found to be associated 
with increased risk for lung cancer and its upregulation was observed in hepatocarcinoma 
[19, 133]. Beyond the scope of its synthetic lethal relationship with the BRCAs, RAD52 
inactivation was demonstrated to augment the immune response and improve therapeutic 
response [73]. 
Development of an effective modulator or inhibitor are usually guided by 
comprehensive structural and biomolecular aspects of the target. For this reason, we 
characterized RAD52 interaction with RPA by SPR, ITC, and FluorIA as described in 
Chapter 3. The data obtained was based on previous work done by our group that 
delineated domains of interactions using an ELISA-based assay [103], stoichiometry by 
SEC-MALS [79], structural analyses by crystallography methods [115],  and 
posttranslational modifications by various experimental methods [134]. 
Here we elaborate on using the FluorIA procedure, described in chapter 1, to conduct 
a high throughput screening for SMIs targeting RAD52:RPA interaction. Over 101,500 
compounds were screened from three different libraries. Eleven candidate hits were 
obtained, five of which showed the strongest inhibition as determined by their high EC50 
values in vitro. Three out of the five are FDA approved and two of these are anti-cancer 
drugs. 
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4.3. Materials and methods 
4.3.1. Chemical libraries screened and handling of compounds. The FluorIA 
procedure described in Chapter 2 was used here to screen for SMIs from three large 
libraries: 1) The 355-member SelleckChem Kinase Inhibitor Library, the 1200-member 
Prestwick Chemical Library, and the 100,000-member ChemBridge library. Compounds 
from each library had been stocked at 10 mM in 100% DMSO and stored at -80 ºC in 384 
plates (Nunc, 267460) termed as “master plates”. Daughter plates are prepared from 
master plates by a 1:5 or 1:50 dilution in 100% DMSO of each compound into new 384-
well clear, round-bottom plates and stored in -20 ºC.  
The screen of the SelleckChem Kinase Inhibitor and the Prestwick were done in two 
concentrations of the drugs: 10 and 100 μM each in duplicate. As we moved to screen the 
large ChemBridge library, we carried out the screen at a single concentration of 100 μM. 
Questionable readings were repeated either as single wells or a whole plate. It was 
possible to screen up to 10,000 compounds in a screen day. At the end of all screens, we 
selected eleven chemicals that met the statistical criteria for a hit as described in Chapter 
2, method section. Each of these hits were further verified in triplicate at 10 and 100 µM 
in a separate FluorIA screen.  
4.3.2. Dose response analysis of hits. Each compound determined to be a hit was taken 
through a secondary screening to confirm its response. Subsequently, as dose response 
curve (DRC) was generated to analyze the half-maximal effective concentration (EC50) 
value in vitro. A source plate is created by hand-pipetting compounds from master plates 
thawed at room temperature starting at 10 mM and serially diluted in half down to 6.0 
µM using 100% DMSO. From each dilution point, a 12 µL/well were hand-pipetted in 
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quadruplicate in a clear, round bottom 384-well source plate. Then100% DMSO was 
pipetted in the same manner in one column of the source plate. Working plates are then 
prepared by first binding 15 pmol/well of freshly purified RPA in the same way described 
in Chapter 2. The RPA plate, however, is not subjected to freezing and is washed and 
blocked. Then FluorIA protocol is followed as described in Chapter 2. Using the Biomek, 
4 uL of each compound or DMSO are transferred from the source plate into the working 
plate. At this point each well contains the experimental or control reaction in a final 
DMSO concentration of 5%. With the addition of 4 µL from each compound in to a 75 
µL reaction mixture, the concentration of chemicals would be reduced approximately 20x 
generating final concentration series that ranges from 500 µM to 0.3 μM. Based on the 
results of these experiments, hits that showed a dose response were ordered. Candidate 
SMIs were purchased and a 1D NMR analyses was carried out to verify their identities. 
Using the molecular weight value, each compound was dissolved in 100% DMSO to 
achieve a stock concentration of 10 mM. Stocks of compounds were aliquoted and stored 
frozen at -20°C. For in vitro DRC experiments, 5 x 103 where the response is the average 
RFU of a triplicate at each concentration point, T0 is the average RFU of a triplicate the 
negative control, and T100 is average RFU of a triplicate the zero-inhibition condition. 
4.3.3. Cancer cell lines. Two cancer cell lines were used: 1) HCC1937 cell line (a 
generous gift from Dr. Simon Powell) is derived from mammary gland, primary ductal 
carcinoma at early onset of a tumor. This triple negative patient carried germ line 
mutation in BRCA1 resulting in COO-terminal truncation protein and loss of the second 
BRCA1 allele. A BRCA1-restored and an empty vector lines were also obtained by 
transfection of a vector containing full-length human BRCA1 cDNA or an empty vector, 
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respectively. 2) PE01 cell line derived from an ovarian cancer patient, with BRCA2 
mutation, ascites at her first relapse post cisplatin chemotherapeutic treatment was 
provided Dr. Tadayoshi Bessho along with a BRCA2-proficient revertant cell line, C4-2. 
The latter line is one of eight clones from cultured PE01with restored BRCA2 due to 
secondary mutation in BRCA2 that cancelled the original mutation as described in Sakai 
et al. [135].  
4.3.4. Cell viability assay. Cells were seeded 5 x 103 cells per well in 96-well plates in a 
90 µL volume per well one day before treatment with exception to the HCC1937 
BRCA1-restored cell line which required a higher density of around 5 x 104 cells per well 
due to consistently observed slow growth and division behavior. For treatment, master 
plates were made from the stock aliquots of compounds described above making 1:2 
serial dilution starting from 10 mM down to 0.02 µM in 100% DMSO. 1:10 dilution was 
made from there in 100% DMSO followed by another 1:10 dilution in cell culture media. 
Finally, 10 µL of this compound solution is transferred onto the 90 µL of cells bringing 
the final DMSO to 1%. Cells in 96-well plates were incubated with increasing 
concentrations, adjusted to the level of sensitivity of the cells to the compound, or vehicle 
control (1% DMSO) for 72 hours. For HCC1937 BRCA1-restord cell line, treatments 
duration was extended to 96 hours accounting for the observed slow division and to allow 
for enough doubling events while in treatment. Each treatment plate contained nine 1:2 
dilution points of a drug in six replicates each: P1 (0–10 μM), P2 or P3 (0–2.5 μM).  Cell 
viability was determined using PrestoBlue reagent (Life Technologies, # A13261). 
Fluorescent measurements were taken using a Spectramax M5 plate reader (MDS). To 
assess cells’ replication in the absence of compounds as a control, six wells on each plate 
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were treated with vehicle to be read in triplicate at the initial treatment day as time zero 
(T0) and at 72-hour read as time 100 (T100).  The PE01 and C-42 cells lines were treated 
in the same manner but due to higher sensitivity, the top concentrations were lower: P1 
(0–5 μM), P2 (0–5 μM), or P3 (0–1.25 μM). 
4.4. Results and discussion 
4.4.1. High throughput screen and hits. Libraries screened, and hits obtained from each 
are summarized in Table 4.1. No hits were obtained from SelleckChem Kinase Inhibitor 
Library as expected. There were three hits from the Prestwick library: P1, P2, and P3 and 
they showed the strong inhibition of RAD52:RPA interaction compared to the rest of the 
hits (Figure 4.1). Eight hits were obtained from the Chembridge library with C2 and C8 
being the strongest inhibition of the RAD52:RPA PPI (Figure 4.2).  Based on their strong 
in vitro inhibition and their significance as FDA-approved drugs, the three Prestwick hits 
were selected for further cell-based characterization.  
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Table 4.1 Chemical libraries screened by FluorIA and hits obtained. 
Chemical Library Hits 
SellekChem none 
Prestwick P1, P2, P3 
Chembridge C1, C2, C3, C4, C5, C6, C7, C8 
P signifies hits from the Prestwick library while C is for Chembrige library.  
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Figure 4.1 Dose response curve and relative inhibition values of Prestwick hits. (A) 
Prestwick drugs were added in the series of concentrations up to 500 µM as described in Materials and 
methods employing the FluorIA. Relative inhibition values were calculated against EGFP tag or 
RAD52(1-303) as controls. (B) Half-maximal effective concentration (EC
50
) for each drug was 
calculated using SigmaPlot 13.0 software with minimum and maximum adjusted to zero and 100 
respectfully. Experiments were repeated three times for each drug. P1 and P3 precipitated in solution 
at high concentrations and data points were eliminated for clarity. 
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Figure 4.2 Dose response curve and relative inhibition values of Chembridge hits (A) 
Chembridge compounds were added in the series of concentrations up to 500 µM to FluorIA reaction 
as described in Materials and methods. Relative inhibition values were calculated against EGFP tag or 
RAD52(1-303) as controls. (B) EC
50
 for each drug was calculated using SigmaPlot 13.0 software with 
minimum and maximum adjusted to zero and 100 respectfully. Experiments were repeated three times 
for each drug. 
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4.4.2 Inhibition of BRCA-deficient cancer cells’ viability following treatments with 
P1, P2, and P3. BRCA1 and BRCA2 are the main pathway in mammalian cells to 
mediate the formation of RAD51 presynaptic filaments and catalyze the repair of DSBs 
by HRR [33, 97]. RAD52, through its interaction with RPA, composes an alternative 
pathway for cells lacking functional BRCA [100]. Targeting RAD52 activity in BRCA-
deficient cancer cells was shown to induce synthetic lethality making it a valuable cancer 
target [58, 59].  
As an initial cell-based assessment, we obtained cancer breast and ovarian cancer cell 
lines with impaired BRCA1 or BRCA2 function and tested their viability with P1, P2, 
and P3 treatments. We rationalized that if these P1, P2, and P3 can inhibit RAD52:RPA 
interaction, BRCA-deficient cell lines will be sensitive to those drugs. For the BRCA1-
deficient HCC1937 triple negative cell line, the results are summarized in Figure 4.3. 
Following 72 or 96-hour treatment with increasing concentrations of either compound P1 
P2, or P3 (0–5 μM) the viability of each cell line was analyzed. The effect of P1 
treatment on viability was difficult to determine with an unexpected spur in overall 
growth behavior. Treatment with P2 reduced cell viability in a dose-dependent manner 
for BRCA1-deficient parental line (not shown) as it did in the empty-vector control while 
inserted BRCA1 plasmid supported survival. P3 treatment indicates an overall cytotoxic 
effect which might have masked any potential difference. Interestingly, treatment with 
lower doses of P2 or P3 showed noticeable spur of growth albeit less than that observed 
with P1.  
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Figure 4.3 BRCA1-defective cancer cell line survival assay. HCC1937 corrected (BRCA+/+), 
empty vector (BRCA-/-), and parental (not shown here) were treated with increasing concentrations of 
(A) P1, (B) P2 and (C) P3 and incubated for three days at 37 °C. Corrected line needed additional 24 
hr. in treatment due to slower growth behavior. PrestoBlue reagent was used to assess the viabilities 
of the treated cells as detailed in Material and methods, and the obtained results were normalized to 
vehicle control. 
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The BRCA2-deficient PE01 ovarian cell line and it BRCA2 restored mutant C4-1 
displayed different patterns of sensitivity. PE01 was sensitive to all three drugs showing 
an overall reduced cell viability in a dose-dependent manner and ~75% inhibition with as 
low as 0.31µM of P2 or P3 treatment. With P1 treatment, 5 µM was needed to reach a 
similar level of inhibition. The interpretation of treatments’ effect for any lower dosages 
was masked by enhanced growth for all three drugs in both cell lines in similar way 
observed with HCC1937 cell lines (Figure 4.4) (lower data point with this issue are 
eliminated for clarity). The EC50 values were determined through curve fitting and are 
summarized in Table 4.2. 
Unlike the HCC1937 with inserted BRCA1 plasmid, C4-2, with restored BRCA2, 
shows evident reduction in viability in a dose-dependent manner with all three drugs 
despite better survival rate than PE01. PE01 was derived from a patient with ovarian 
adenocarcinoma at stage III who was sensitive initially to cisplatin and AG14361 PARP 
inhibitor. However, she acquired cisplatin resistance and PARP inhibition resistance upon 
a secondary revertant point mutation in BRCA2 [135, 136].  
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Figure 4.4 BRCA2-defective cancer cell line survival assay PE01 and C4-2 cell lines were treated 
with increasing concentrations of (A) P1, (B) P2 and (C) P3 and incubated for three days at 37°C. 
PrestoBlue reagent was used to assess the viabilities of the treated cells as detailed in Material and 
methods, and the obtained results were normalized to vehicle control. 
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Table 4.2 EC
50
 for P1, P2, and P3-treated PE01 and C4-2. 
Cell line P1 P2 P3 
PEO1 2.9 (0.32) 0.11 (0.036) 0.15 (0.07) 
C4-2 5.4 (0.62) 0.37 (0.12) 0.43 (0.29) 
EC
50
values here are experimental replicates with technical triplicates.  
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C4-2 was among several PE01 clones obtained after four weeks in culture where 
BRCA2 was restored. Functional significance of this type of restoration is unclear 
particularly with the heterogeneity in resistance observed among these clones. No reports 
of administering the anti-cancer P2 or P3 drugs in that patient’s chemotherapeutic rounds 
after acquiring this secondary BRCA2 mutation were found. This data here suggest a level 
of sensitivity in C4-2 and might be of therapeutic value to explore whether RAD52:RPA 
inhibition bolstered this sensitivity.  
The observed inhibition of the viability for these artificial BRCA2 mutants suggest an 
impact on alternative repair and survival pathway in the absence of BRCA2. In addition 
to the finding of the screen with respect to inhibition of RAD52:RPA interaction, further 
work is needed to validate whether RAD52 activity is specifically targeted here and 
whether that explains the compromised survival observed in BRCA-deficient cell line. 
Collectively, cell viability assays revealed higher potency for P2 and therefore, it was 
selected for this analysis.  
The viability tests above guided a general understanding of BRCA-deficient cell lines 
sensitivities to these three hit drugs. However, the varying phenotype and heterogeneity 
in response were inevitable features of cancer cell lines. To validate inhibition of 
RAD52:RPA interaction as we found in FluorIA, it was is necessary to examine drugs’ 
effect on specialized RAD52 pathway.  
RAD52 is a primary driver of SSA type of HR where a search for homology usually 
carried by RAD51 is dispensable when DSBs take place within direct repeats. RPA 
covers the ssDNA exonuclease products at the DSB site and through interaction with 
RAD52 ends are re-joining concludes the repair process with inevitable deletion of 
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flanking sequences between the direct repeats. Pretreatment of SA-GFP U2OS with P2 
was done by Dr. Bessho prior to expression of I-SceI and analysis by flow cytometry. 
Similar treatment was carried out using D-I03, a RAD52 inhibitor recently published by 
Dr. Mazin’s group [63]. DSBs repair activity by SSA was scored by GFP+ cells and 
blotted as a function of P2, D-I03, or vehicle treatment. As will be soon reported in a 
manuscript for publication, with 5 nM, P2 lowered SSA activity by over 50%, which is 
4000-fold less concentration than D-I03 to reach this effect. The data suggests that 
RAD52 repair activity is part of the mechanism of action for P2 and can be of great value 
to explain the varied sensitivity to this drug among cancer patients.  
4.5. Conclusion 
RAD52 repair activity is valuable for the progress of tumorigenesis and we have 
demonstrated through multidisciplinary studies that its complex with RPA is a candidate 
to target for the development of selective anti-cancer therapies. While development of a 
new targeted cancer drugs is an ambitious goal that we strive for, investigating the 
mechanism of action of existing anti-cancer drugs should be a concomitant effort. As we 
are understanding more about the genetic background behind cancer, it is vital to revisit 
the therapeutic drugs in use and delineate the molecular maps behind their sensitivities 
and resistance.  The outcome of such studies will be of great benefit to the clinical 
assignment of candidate patients for such drugs, building on the goal of personalized 
medicine in cancer therapeutics. 
We identified eleven potential SMIs for RAD52 interaction with RPA to induce 
synthetic lethality in BRCA-deficient tumors. Surprisingly, three of those hits were FDA-
approved drugs, two of which are known for their anti-cancer activities. While the 
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general mechanism of these two drugs are known, varied sensitivities to them in patients 
is not completely understood. Our work here leads to molecular clues that may explain 
that variation. We show selective targeting of P2 to RAD52 repair activity; however, 
further work is needed to identify its selectivity to RAD52 proteins and ways to enhance 
its inhibitory action. 
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Chapter 5 
Conclusion and future directions 
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A common starting feature in malignancies is uncontrolled cell division. There are 
molecular factors that enable such behavior and others that work to maintain it in the face 
of all defense mechanisms our bodies had developed. DNA damage and repair are central 
processes in cancer and candidate enabling and maintenance factors can be identified 
within these pathways. 
RAD52 is currently recognized to promote tumorigenesis because of its crucial roles 
in a number of repair activities at DNA damage stress sites. RAD52 repair activity was 
specifically explored in different cancers and affirmed to be parallel to maintenance of 
cancer cells’ survival. Work by Cramer-Morales and colleagues showed that BCR-
ABL1- mediated leukemia (BRCA1-deficient) relies on RAD52 to repair increased levels 
due to enhanced ROS-induced damage [60]. Remarkably, their work also showed that 
depletion of RAD52 suppressed both cancer stem and progenitor cells expansion and 
increased their apoptosis. In support of their work, a recent RAD52-/- mice model not 
only demonstrated resistance to squamous cell lung carcinoma, but also augmented the 
activity of CD8+ T cells and NK effectors [73]. 
Our work focused on characterizing the candidacy of RAD52 interaction with RPA as 
a cancer target and development of a high throughput assay to screen libraries of SMIs 
for this interaction. Previous successes scored in targeting PPIs was attributed to 
thorough, multidisciplinary characterization of protein targets. Targeting PPI to inhibit or 
modulate their activity is becoming an attractive approach in various therapeutics due to 
their observed altered behavior of interaction or expression in disease. Large PPI 
interfaces had traditionally posed a challenge for the idea of being modulated by small 
molecules. However, protein mutational studies demonstrated that only some residue 
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areas or “hot spots” may provide the binding energy for the small molecules to bind and 
exclude the targeted protein partner [85, 90]. Successful HTS screens, for example, have 
been credited for the discoveries of most enzyme-targeted small molecules that were later 
adapted for other protein targets. To name a few, NMR-based screens [91], differential 
scanning fluorimetry (DSF) [92], and 3D molecular modeling to select candidates for 
HTS [94].  
While these were useful approaches, their applications is usually costly and requires 
the presence of specific instruments that are not readily available for every researcher. 
FluorIA (Chapter 2) has no demand for expensive instrumentation yet is a robust and 
homogeneous assay. We were able to screen large libraries of molecules with efficacy in 
time, cost, and output. On a low-scale, FluorIA was proved valuable use in detecting PPIs 
using full-length or truncated mutant proteins. This was particularly useful in delineating 
the domains of interactions and coordinating such data with available kinetic and 
structural data to characterize RAD52 interaction with RPA (Chapter 3).  
The libraries we screen yielded interesting potential SMIs in terms of identity and 
structure (Chapter 4). We focused particular attention on the three FDA-approved drugs 
hits. We characterized several BRCA1/2-deficient cancer cell lines’ survival with these 
three hits treatment. Despite the challenges encountered with the heterogeneous behavior 
of culturing cancer cell lines, we observed a general survival in the presence of 
BRCA1/2. P2, being an anti-cancer drug was particularly interesting. The data we have 
suggest that targeting RAD52 repair activity might be part of the mechanism of action for 
P2 and can be of great value to explain the varied sensitivity to this drug among cancer 
patients.  
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Understanding the mechanism of action of existing anti-cancer drugs is equally 
important as discovering new ones. Varied resistance and sensitivities to current therapies 
has always been a challenge and delineating the molecular basis for this variation is 
valuable in the quest for personalized cancer therapy. A great example for this was 
demonstrated through vorinostat, a drug that showed significant success in reducing brain 
metastases particular experienced by TNBC patients. The known mechanism-of-action 
for vorinostat was its action as a histone-modifying agent [137]. Palmier and colleagues 
demonstrated that decreased RAD52 expression augments vorinostat’s action by 
promoting accumulation of unrepaired DSBs [138]. 
In clinical literature, P2 was reported to have the highest anti-cancer activity in 
patients with BRCAness. There is a generally accepted mechanism of action for P2 that 
does not address the varied sensitivity in BRCA-deficient tumors. Interestingly, there are 
reported efforts to sensitize other non BRCA-deficient subtypes of breast cancers to P2 
through targeting other DNA repair pathways. Accordingly, we anticipate that our 
research will explain a new mechanism-of-action in which the success in P2 use with 
BRCA-deficient breast or ovarian cancer patients might be attributed to the synthetic 
lethality achieved by inhibition of RAD52 activity.  
We will further characterize the eleven potential SMIs, particularly the strongest five, 
by in vivo and in vitro experiments. Additional future work will include determining the 
protein partner binding (RPA or RAD52) and the affinity of binding. We will also use 
protein painting method and crystallography to further understanding binding pockets and 
interacting residues [139]. With the knowledge we have of interacting domains of RPA 
on RAD52, we plan to link the best of the SMI with each other or with other published 
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SMIs which inhibit binding directly to ssDNA to achieve more specific binding and 
selective targeting of RAD52. 
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Appendix I. 
RAD52 peptides design and analysis in the 
FluorIA 
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Introduction 
The RPA32(172-270) wHLH region is known to be a site for PPI. The interaction 
interfaces of UNG2, XPA, and RAD52 with this region has been examined by NMR 
analyses. Residues of UNG2 protein involved in long-range Nuclear Overhauser 
enhancements (NOEs) were aligned with corresponding residues of XPA and RAD52 
[121]. We used the RAD52(257-274) from this group plus an additional eleven RAD52 
peptides based on analyses of the RAD52(1-212) crystal structure in the FluorIA assay to 
further investigate the overall RAD52:RPA interaction domains. The rational for peptides 
was that this is a route frequently used to find PPI inhibitors.  
Method 
RAD52 peptides. Eleven RAD52 peptides were designed and purchased (China peptide) 
(Table A1.1, peptides 1-11). The full RAD52(257-274) peptide was obtained as well 
(GenScript) (Table A1.1, peptide 12). A stock was made at of RAD52(257-274) at10 mM 
using nuclease-free water and stored frozen at -20 °C. All other peptides were peptides 
were diluted to 10 mM using DMSO and stored frozen at -20 °C. 
Two peptides (260-RQKQQQFR-269 and 253-ATHQRKLRQK-262) were generated 
from NMR analysis where UNG2 residues involved in intermolecular NOE signals were 
assigned, and the corresponding alignments with RAD52(257-274) were determined for 
interaction with RPA32(172-270) [121]. An additional peptide (269-RERMEKQQVR-
278) was made from the last segment of RAD52(257-274). The remaining eight peptides 
were designed from structural analysis of the self-association domain of RAD52 [119].  
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Table A1.1 The sequences RAD52 peptides  
Peptide Amino acid sequence 
Rational for 
design 
Peptide 1 34-EEYQAIQKAL-43 
R
A
D
5
2
 self-a
sso
cia
tio
n
 
Peptide 2 42-ALRQRLGPEY-51 
Peptide 3 69-HRVINLANEM-78 
Peptide 4 81-YNGWAHSITQQ-91 
Peptide 5 115-LKDGSYHEDV-124 
Peptide 6 141-KARKEAVTDG-150 
Peptide 7 167-LDKDYLRS-174 
Peptide 8 191-AKRQDKEPSV-200 
Peptide 9 253-ATHQRKLRQK-262 
R
P
A
-b
in
d
in
g
 
d
o
m
a
in
 
Peptide 10 260-RQKQLQQQFR-269 
Peptide 11 269-RERMEKQQVR-278 
Peptide 12 257-RKLRQKQLQQQFRERMEK-274) 
R
P
A
 
b
in
d
in
g
 
reg
io
n
 
RAD52 short peptides with labeled as P1-P11 with their amino acid sequences. 
RAD52(257-274) peptide labeled P12. 
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Screening peptides by FluorIA. Each peptide was added first to a single well of the 
FluorIA reaction as an inhibitor at 100 and 10 μM in the same manner described Chapter 
2 (Figure A1.1). Additional FluorIA assays were done with peptide combinations to look 
for any potential synergetic inhibitory effects. The final concentration of each peptide in 
the synergy reaction was 50 μM per well. The layout for the experiment is shown in 
Figure A1.2. This experiment will be redone at 100 μM in the future. 
Results 
In FluorIA, peptide1-11 was added at 10 or 100 μM in the hope of detecting an 
inhibitory effect. No signal reduction was detected from any single peptide (Figure A1.1) 
or synergy combination of two peptides per well at 50 μM (Figure A1.2).  
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Figure A1.1 FluorIA results with RAD52 peptides in singles. Heat map created by R studio 
using FluorIA data testing each of the RAD52 peptides as potential SMIs for RAD52:RPA 
interaction. The red colored column (column 1) has low RFU readings as a result of inhibition 
by Rad52(1-303) and servers as a positive control. The eleven peptides are laid out 
horizontally row 1-7 (row 1 and 2) with 10 μM on top and 100 μM in the bottom (row 3 and 
4). Column 8 is a negative control. 
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1 2 3 4 5 6 7 8 9 10 11
1 P1:P1 P1:P2 P1:P3 P1:P4 P1:P5 P1:P6 P1:P7 P1:P8 P1:P9 P1:P10 P1:P11
2 P2:P1 P2:P2 P2:P3 P2:P4 P2:P5 P2:P6 P2:P7 P2:P8 P2:P9 P2:P10 P2:P11
3 P3:P1 P3:P2 P3:P3 P3:P4 P3:P5 P3:P6 P3:P7 P3:P8 P3:P9 P3:P10 P3:P11
4 P4:P1 P4:P2 P4:P3 P4:P4 P4:P5 P4:P6 P4:P7 P4:P8 P4:P9 P4:P10 P4:P11
5 P5:P1 P5:P2 P5:P3 P5:P4 P5:P5 P5:P6 P5:P7 P5:P8 P5:P9 P5:P10 P5:P11
6 P6:P1 P6:P2 P6:P3 P6:P4 P6:P5 P6:P6 P6:P7 P6:P8 P6:P9 P6:P10 P6:P11
7 P7:P1 P7:P2 P7:P3 P7:P4 P7:P5 P7:P6 P7:P7 P7:P8 P7:P9 P7:P10 P7:P11
8 P8:P1 P8:P2 P8:P3 P8:P4 P8:P5 P8:P6 P8:P7 P8:P8 P8:P9 P8:P10 P8:P11
9 P9:P1 P9:P2 P9:P3 P9:P4 P9:P5 P9:P6 P9:P7 P9:P8 P9:P9 P9:P10 P9:P11
10 P10:P1 P10:P2 P10:P3 P10:P4 P10:P5 P10:P6 P10:P7 P10:P8 P10:P9 P10:P10 P10:P11
11 P11:P1 P11:P2 P11:P3 P11:P4 P11:P5 P11:P6 P11:P7 P11:P8 P11:P9 P11:P10 P11:P11
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Figure A1.2 RAD52 peptide synergy analysis. RAD52 peptides screened as small 
molecule inhibitors in pairs according to the FluorIA method described in Chapter 1. The 
final concentration of each peptide in a well is 50 µM. 
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Appendix II 
Additional cell lines for survival analysis with 
candidate hits 
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Cancer cell lines 
1) EUF423 cell line. This cell line contains biallelic truncation of the COOH-terminal 
region of both BRCA2 genes also obtained from Dr. Simon Powell along with restored 
BRCA2 line. The stable transfection procedures along with culturing conditions for each 
cell line are described in Treszezamsky et al., [140]. 
2) Capan-1 cell lines. Three Capan-1 cell lines were also tested with our hits: BRCA2 
mutant Capan-1-neo, empty vector, and is BRCA2-corrected Capan-1-236-BRCA2. 
These lines were cultured in DMEM with glutamine, supplemented with 20% FBS, 
100U/mL penicillin, 100ug/mL streptomycin. 
Western Blot. Cell lysates were separated by 6% SDS-PAGE and BRCA1, BRCA2, 
HA-tagged BRCA1 were analyzed by western blots. The Antibodies (Abs) used are: 
affinity purified rabbit anti-BRCA1 Ab (Bethyl, #A301-377A), anti-BRCA2 (Ab-1) 
mouse monoclonal clone 2B (EMD Millipore, OP95), ECL anti-rabbit IgG-HRP HA (GE 
Life Sciences, #NA934), and ECL anti-mouse IgG-HPR (GE Life Sciences, #NA931). 
Bands were detected using ECL Clarity (BioRad). 
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Figure A2.1 Western blot analysis for BRCA1 and BRCA2 status in HCC1937 and EUFA432 cell lines. 
(A) Left: HCC1937 corrected (3rd lane labeled B1) show a band for BRCA1. None was detected in empty 
vector (labeled as “V”) or parental line (labeled as “-“). Right: EUFA423 cell line showed a BRCA1 band in 
both parental (labeled as “-“) and corrected (labeled as HA-B2). (B and C) Repeats of the EUFA423 lines 
listed above with two regular anti-BRCA2 antibodies and two anti-HA antibodies. The results show that the 
corrected EUFA423 might have lost its BRCA2 insert plasmid. Upon treatment with P1, P2, and P3; no 
difference in survival was observed. The level of BRCA2 expression could be have been sufficient to rescue 
cellular phenotype. 
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Results 
No difference was observed in survival upon treatment of parental or BRCA1/2 
plasmid-inserted derivative of Capan-1 or EUFA423 cell lines respectively. A western 
blot analysis revealed residual BRCA2 in EUFA423 that might have contributed to equal 
survival (Figure A2.1B and C).   
Non-cancer CRISPR-generated BRCA2 mutant cell lines.   
HeLa-DR cell line that was specifically designed homology-mediated gene conversion 
(HR) was used to generate BRCA2 mutants by CRISPR/Cas9 technology. Expression of 
BRCA2 in CRISPR-generated BRCA2 mutants. Whole cell lysate was prepared from 
each cell line and the levels of BRCA2 protein were examined by western blots.  A large 
subunit of RPA, p70, was used as loading control.  A parental HeLa-DR that contains 
wild type BRCA2 and two BRCA2 mutants: g2-10 and g2-37. Each cell line was seeded 
at 300 cells/well in 24-well plates and grew overnight. The cells were treated with the 
indicated concentrations of MMC for one day.  After removing MMC, the cells were 
grown in fresh medium for 4-5 days until colonies formed.  The cells were stained by 
crystal violet, the numbers of colonies were counted, and surviving fraction was 
determined. A HeLa-derived cell line, HeLa-DR-13-9 (a generous gift from Dr. Jeffrey 
Parvin at the Ohio State University) was used to measure HR activity. Each cell line was 
seeded at 3 x 104 cells per well in 12-well plates one day before transfection. The cells 
were transfected by the expression plasmid of I-SceI endonclease (a generous gift from 
Dr. Maria Jasin at Memorial Sloan Kettering Cancer Center) to induce DSBs. On the 
third day of the transfection, the HR activity (scored as GFP positive cells) was 
determined by FACS.  
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Results 
The effect of treatment with P1, P2, and P3 on wt.HeLa (DR) and the BRCA2 
mutants’ survival was examined in the same manner described above with cancer cell 
lines. However, due to reported higher sensitivity of HeLa cell lines to DNA-damaging 
agents treatment with lower doses of concentration series were done. As seen in Figure 
A2.2, treatment with P3 showed the most sensitivity compared with treatment of P2 
while treatment with P1 impact the wt.HeLa line and higher concentration series of it was 
needed to observe the effect. 
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Figure A2.2 CRISPR-generated BRCA2 mutants HeLa-DR, BRCA2 mutants. The 
g2-10, BRCA2 mutant g2-37 were treated with increasing concentrations of (A) P1, (B) 
P2 and (C) P3 and incubated for three days at 37°C. PrestoBlue reagent was used to 
assess the viabilities of the treated cells as detailed in Material and methods, and the 
obtained results were normalized to vehicle control. 
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Appendix III 
Development of SSA activity assay 
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Introduction 
Sugiyama and co-workers exploited the selective binding of DAPI dsDNA to 
fluorescently follow the annealing activity of a Rad52:RPA complex in the presence of a 
heat-denatured DNA plasmid [75]. Their work demonstrated the important role for RPA 
in promoting SSA activity of RAD52. Given our great interest in RAD52 interaction with 
RPA, we developed a similar but more robust SSA activity assay employing longer DNA 
in the reaction, human proteins, and a much more sensitive method of detection (SYBR 
Dyes) that exhibits >1000-fold fluorescence enhancement upon binding to nucleic acids 
and has a high quantum yield (~0.6) upon binding to ds or ssDNA  [141]. 
Method 
Purified 8D-RPA and RAD52 (Figure A3.1 A and B respectively) were used in this 
assay. Purification for each followed the same protocol detailed in Chapter 2. A 50 ng of 
pBlueScript KS(+/-) plasmid DNA linearized by Scal (dsDNA) and heat-denatured 
linearized (hdDNA). The hdDNA was preincubated with 8D-RPA for one hour before the 
addition of RAD52 in a 1:2 ratio. The products were separated by 1% agarose gel (100 
voltage for 1 hour and 40 minutes in 1x TAE buffer). SYBR stains (SYBR Green for 
dsDNA and SYBR Gold for both dsDNA and ssDNA, Molecular Probes) were diluted in 
1x TAE buffer according to manufacturer instructions and used to stain the gels for 20 
minutes before washing 2x with ddH2O and imaging with Safe Imager 2.0 (Invitrogen).  
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RAD52 
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Figure A3.1 SDS-PAGE gel of purified protein constructs. A) Purified 
hetero-trimeric 8D-RPA. B) Different constructs of RAD52 shown from 
left to right: full length RAD52, full-length RAD52 with an EGFP tag, and 
RAD52(1-212) construct. 
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Results 
We observed the characteristic hdDNA band at about ~2900 base pair (Figure A3.2, red 
box) disappeared in the presence of 8D-RPA and a band above the 10,000 base-pair mark 
appeared, (Figure A3.2, blue box), indicating multiple RPAs binding to the ssDNA. 
RAD52:DNA cpmplex have been noted to accumulate as large molecular weight 
aggregates in the gel wells [142]. Our result confirms this phenomoneon, as seen in the last 
four lanes containing decreasing concentrations of RAD52 added to an RPA-bound 
ssDNA. Nevertheless, we demonstrated the annealing of the plasmid as indicated by the 
dose-related reappearance of the dsDNA at its expected size of 3500 bp. We will use this 
assay to test the effect of RPA phosphorylation and candidate SMIs on RAD52 activity.  
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Figure A3.2 RAD52 SSA assay. Gel based assay using 8D-RPA and RAD52. 
The gel was stained with SYBR Gold and our interpretation was confirmed with 
SYBR Green (not shown).  
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Appendix IV 
8D-RPA SAXS analysis 
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Introduction 
RPA is phosphorylated in a cell cycle-dependent manner to regulate its interaction 
with DNA and protein partners. Specific phosphorylation events on multiple serine 
residues of RPA32 subunit as this site is a hub for PPI, including RAD52. An RPA 
phosphmimic was created by Wolds and co-workers to mimic hyperphosphorylated RPA. 
It contains the following mutations on RPA32: S8D, S11D, S12D, S13D, T21D, S25D, 
S29D, and S33D.  
It has not been possible to obtain full structural data on RPA using crystallography or 
NMR due to flexible nature of the regions linking the different domains. Here we used 
SAXS to analyze an overall low-resolution structural measurement of 8DRPA. 
Methods 
The plasmid for 8D RPA was a generous gift from Dr. Marc Wolds. Transformation 
was done into Rosetta2(DE3). Expression and growth were the same as described for 
RPA in chapter 2 with the addition of purification using size exclusion column with 300 
mM KCl in HI-0 buffer described in Chapter 2. Fractions were then collected 
individually and assessed by DLS for monodispersity.  
Two monodispersed samples were obtained, and concentrations were determined by 
NanoDrop1000. The two samples were concentrated separately using spin concentrators 
(30,000 MWCO) achieving 6 mg/mL and 8 mg/mL. The flow-through resulting from the 
concentration process was collected to use as blank buffer in SAXS analysis. Column 
void volume is the buffer volume before the elution of the protein in the size exclusion 
purification step was also collected for the same purpose.  
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Images were collected for 1.5 hours at room temperature on Rigaku BioSAXS 1000 
system with an FR-E rotating anode X-ray generator (λ= 1.54 Å). Resulting data were 
processed using Automated Analysis Pipline in SAXSLab software which provides a 
GUI for the ARSAS Package (Rigaku). The buffer effect was automatically subtracted by 
the software and the Guinier plot, radius of gyration, molecular weight and volume, pair 
distribution function, Kratky plot, an infinite dilution scattering curve, and ab initio bead 
model fits to the data were calculated as well. Finally, Dmax was calculated from the X-
intercept of the P(r) curve were calculated. Models were generated using PyMOL 
(SchrÖdinger, LLC). 
Results and discussion 
SAXS is a low-resolution technique that is of great value to obtain an overall shape 
and dimension data that can be paired with higher resolution structural data from 
crystallography or NMR techniques. It is also a feasible technique to analyze full-length 
proteins in solution [143].  At the time of this investigation, we had the 8DRPA 
expression and purification resolved and therefore was used in the SAXS analysis. We 
anticipated no difference from the wild-type RPA. The data were collected over two 
concentrations: 6 and 8mg/mL that were checked for monodispersity using DLS.  
The scattering pattern indicate q of about 0.2 demonstrating less noise and good 
quality data at the concentrations analyzed (Figure A4.1 A). Using the Guinier 
approximation and scattering data, the radius of gyration (Rg) was obtained and reported 
in table A4.1. Kratky plot shown in figure A3.1B indicates partial folding as the curves 
increase at higher q values after reaching a peak. Finally, maximum dimensions (Dmax) 
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(Table A4.1) was calculated from the probability distribution function, P(r), plot (Figure 
A4.1C). The maximum dimension for 8DRPA seems to be around 175 Å. 
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Figure A4.1 SAXS profile data for 8DRPA. A) SAXS scattering, B) Kratky plot, C) 
probability distribution of 8DRPA at the two different concentrations analyzed.  
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Table A4.1 Predictions of 8DRPA dimension values.  
8DRPA concentration (mg/mL) Rg Dmax 
6 49 166 
8 51 173 
SAXSLab software calculation of the radius of gyration (Rg) using the SAXS 
scattering pattern and maximum dimension (Dmax) using from the x-intercept of the 
P(r) curve.  
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The relative topology of 8DRPA is demonstrated by the Ab initio bead models that 
were fit to the P(r) function. The molecular envelop shows an extended structure for the 
most parts of the protein with semi-globular conformation in most of the central and 
terminal region (Figure A4.2).  
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Figure A4.2 SAXS model for 8DRPA.  
Ab initio bead models to predict the molecular envelop of full-length 8DRPA. 
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